00015853642024FYFALSEhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#AssetImpairmentChargeshttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#RevenueFromContractWithCustomerExcludingAssessedTaxiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesiso4217:EURxbrli:sharesprgo:reporting_unitxbrli:pureprgo:productprgo:transactioniso4217:EURprgo:derivativeprgo:yearprgo:classprgo:stateprgo:manufacturerprgo:employeeprgo:hospitalprgo:plaintiffprgo:individualprgo:claimiso4217:ILSiso4217:USDiso4217:ILSprgo:policy_period00015853642024-01-012024-12-310001585364prgo:OrdinaryShares0001ParValueMember2024-01-012024-12-310001585364prgo:A4.900SeniorNotesDue2030Member2024-01-012024-12-310001585364prgo:A6.125SeniorNotesDue2032Member2024-01-012024-12-310001585364prgo:A5.375SeniorNotesDue2032Member2024-01-012024-12-310001585364prgo:A5.300SeniorNotesDue2043Member2024-01-012024-12-310001585364prgo:A4.900SeniorNotesDue2044Member2024-01-012024-12-3100015853642024-06-2800015853642025-02-2100015853642023-01-012023-12-3100015853642022-01-012022-12-3100015853642024-12-3100015853642023-12-3100015853642022-12-3100015853642021-12-310001585364us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-12-310001585364us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001585364us-gaap:RetainedEarningsMember2021-12-310001585364us-gaap:RetainedEarningsMember2022-01-012022-12-310001585364us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001585364us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-01-012022-12-310001585364us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-12-310001585364us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001585364us-gaap:RetainedEarningsMember2022-12-310001585364us-gaap:RetainedEarningsMember2023-01-012023-12-310001585364us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001585364us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-01-012023-12-310001585364us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-12-310001585364us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001585364us-gaap:RetainedEarningsMember2023-12-310001585364us-gaap:RetainedEarningsMember2024-01-012024-12-310001585364us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001585364us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-01-012024-12-310001585364us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-12-310001585364us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001585364us-gaap:RetainedEarningsMember2024-12-310001585364us-gaap:ForeignExchangeForwardMember2024-01-012024-12-310001585364prgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364country:US2024-01-012024-12-310001585364country:US2023-01-012023-12-310001585364country:US2022-01-012022-12-310001585364srt:EuropeMember2024-01-012024-12-310001585364srt:EuropeMember2023-01-012023-12-310001585364srt:EuropeMember2022-01-012022-12-310001585364prgo:OtherGeographicalAreasMember2024-01-012024-12-310001585364prgo:OtherGeographicalAreasMember2023-01-012023-12-310001585364prgo:OtherGeographicalAreasMember2022-01-012022-12-310001585364country:IE2024-01-012024-12-310001585364country:IE2023-01-012023-12-310001585364country:IE2022-01-012022-12-310001585364prgo:UpperRespiratoryMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:UpperRespiratoryMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:UpperRespiratoryMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:DigestiveHealthMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:DigestiveHealthMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:DigestiveHealthMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:NutritionMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:NutritionMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:NutritionMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:PainAndSleepAidsMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:PainAndSleepAidsMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:PainAndSleepAidsMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:HealthyLifestyleMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:HealthyLifestyleMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:HealthyLifestyleMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:OralCareMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:OralCareMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:OralCareMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:SkincareAndPersonalHygieneMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:SkincareAndPersonalHygieneMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:SkincareAndPersonalHygieneMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:WomensHealthMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:WomensHealthMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:WomensHealthMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:VitaminsMineralsAndSupplementsMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:VitaminsMineralsAndSupplementsMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:VitaminsMineralsAndSupplementsMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:OtherCSCAMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:OtherCSCAMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:OtherCSCAMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364prgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364prgo:ConsumerSelfCareAmericasMember2022-01-012022-12-310001585364prgo:SkincareAndPersonalHygieneMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:SkincareAndPersonalHygieneMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:SkincareAndPersonalHygieneMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:UpperRespiratoryMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:UpperRespiratoryMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:UpperRespiratoryMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:HealthyLifestyleMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:HealthyLifestyleMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:HealthyLifestyleMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:PainAndSleepAidsMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:PainAndSleepAidsMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:PainAndSleepAidsMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:VitaminsMineralsAndSupplementsMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:VitaminsMineralsAndSupplementsMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:VitaminsMineralsAndSupplementsMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:WomensHealthMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:WomensHealthMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:WomensHealthMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:OralCareMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:OralCareMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:OralCareMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:DigestiveHealthMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:DigestiveHealthMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:DigestiveHealthMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:OtherCSCIMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:OtherCSCIMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:OtherCSCIMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364prgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364prgo:ContractManufacturingMember2024-01-012024-12-310001585364prgo:ContractManufacturingMember2023-01-012023-12-310001585364prgo:ContractManufacturingMember2022-01-012022-12-310001585364prgo:RareDiseasesBusinessMember2024-07-100001585364prgo:RareDiseasesBusinessMember2024-07-102024-07-100001585364prgo:RareDiseasesBusinessMember2024-06-292024-06-290001585364prgo:BrandedProductsMember2024-01-012024-12-310001585364prgo:BrandedProductsMember2024-12-310001585364prgo:HospitalSpecialtyBusinessMember2024-11-010001585364prgo:HospitalSpecialtyBusinessMember2024-11-012024-11-010001585364prgo:HospitalSpecialtyBusinessMember2024-09-282024-09-280001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:AdventInternationalMember2022-03-090001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:AdventInternationalMember2022-03-092022-03-090001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2022-03-090001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:LatinAmericaBusinessMember2022-03-092022-03-090001585364prgo:ScarAwayMemberprgo:ConsumerSelfCareInternationalMember2022-03-242022-03-240001585364prgo:HRAPharmaMember2022-04-290001585364prgo:HRAPharmaMember2022-04-292022-04-290001585364prgo:HRAPharmaMember2022-04-292022-12-310001585364prgo:HRAPharmaMember2022-01-012022-12-310001585364prgo:HRAPharmaMemberus-gaap:TrademarksAndTradeNamesMember2022-04-290001585364prgo:HRAPharmaMemberus-gaap:DevelopedTechnologyRightsMember2022-04-290001585364prgo:HRAPharmaMemberprgo:DistributionNetworksMember2022-04-290001585364prgo:HRAPharmaMemberus-gaap:InProcessResearchAndDevelopmentMember2022-04-290001585364prgo:ConsumerSelfCareAmericasMember2022-04-292022-04-290001585364prgo:ConsumerSelfCareInternationalMember2022-04-292022-04-290001585364prgo:HRAPharmaMemberus-gaap:TrademarksAndTradeNamesMember2022-04-292022-04-290001585364prgo:HRAPharmaMemberus-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2022-04-292022-04-290001585364prgo:HRAPharmaMemberus-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2022-04-292022-04-290001585364prgo:HRAPharmaMemberprgo:DistributionNetworksMembersrt:MinimumMember2022-04-292022-04-290001585364prgo:HRAPharmaMemberprgo:DistributionNetworksMembersrt:MaximumMember2022-04-292022-04-290001585364prgo:NestlesGatewayInfantFormulaPlantAndGoodStartInfantFormulaMember2022-11-012022-11-010001585364prgo:NestlesGatewayInfantFormulaPlantAndGoodStartInfantFormulaMember2022-01-012022-12-310001585364prgo:NestlesGatewayInfantFormulaPlantAndGoodStartInfantFormulaMember2022-11-012022-12-310001585364prgo:NestlesGatewayInfantFormulaPlantAndGoodStartInfantFormulaMember2022-11-010001585364prgo:NestlesGatewayInfantFormulaPlantAndGoodStartInfantFormulaMemberprgo:DistributionAndLicenceAgreementsAndSupplyAgreementsMember2022-11-010001585364prgo:NestlesGatewayInfantFormulaPlantAndGoodStartInfantFormulaMemberprgo:CustomerRelationshipsAndDistributionNetworksMember2022-11-010001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:RXPharmaceuticalsMember2021-07-060001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:RXPharmaceuticalsMember2021-07-062021-07-060001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:RXPharmaceuticalsMember2024-01-012024-12-310001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:RXPharmaceuticalsMember2023-01-012023-12-310001585364us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberprgo:RXPharmaceuticalsMember2022-01-012022-12-310001585364us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310001585364us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001585364us-gaap:OtherNoncurrentAssetsMember2024-12-310001585364us-gaap:OtherNoncurrentAssetsMember2023-12-310001585364us-gaap:LandMember2024-12-310001585364us-gaap:LandMember2023-12-310001585364srt:MinimumMemberus-gaap:BuildingMember2024-12-310001585364srt:MaximumMemberus-gaap:BuildingMember2024-12-310001585364us-gaap:BuildingMember2024-12-310001585364us-gaap:BuildingMember2023-12-310001585364srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310001585364srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310001585364us-gaap:MachineryAndEquipmentMember2024-12-310001585364us-gaap:MachineryAndEquipmentMember2023-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareAmericasMember2024-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareAmericasMember2023-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareInternationalMember2024-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareInternationalMember2023-12-310001585364us-gaap:MaterialReconcilingItemsMember2024-12-310001585364us-gaap:MaterialReconcilingItemsMember2023-12-310001585364prgo:ConsumerSelfCareAmericasMember2022-12-310001585364prgo:ConsumerSelfCareInternationalMember2022-12-310001585364prgo:ConsumerSelfCareAmericasMember2023-12-310001585364prgo:ConsumerSelfCareInternationalMember2023-12-310001585364prgo:ConsumerSelfCareAmericasMember2024-12-310001585364prgo:ConsumerSelfCareInternationalMember2024-12-310001585364us-gaap:OperatingSegmentsMemberprgo:RareDiseasesReportingUnitMemberprgo:ConsumerSelfCareInternationalMember2024-03-312024-06-290001585364us-gaap:OperatingSegmentsMemberprgo:RareDiseasesReportingUnitMemberprgo:ConsumerSelfCareInternationalMember2023-10-012023-12-310001585364us-gaap:OperatingSegmentsMemberprgo:HospitalAndSpecialtyBusinessReportingUnitMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364prgo:TrademarksTradeNamesAndBrandsMember2024-12-310001585364prgo:TrademarksTradeNamesAndBrandsMember2023-12-310001585364us-gaap:InProcessResearchAndDevelopmentMember2024-12-310001585364us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001585364us-gaap:LicensingAgreementsMember2024-12-310001585364us-gaap:LicensingAgreementsMember2023-12-310001585364us-gaap:DevelopedTechnologyRightsMember2024-12-310001585364us-gaap:DevelopedTechnologyRightsMember2023-12-310001585364us-gaap:CustomerRelationshipsMember2024-12-310001585364us-gaap:CustomerRelationshipsMember2023-12-310001585364prgo:TrademarksTradeNamesAndBrandsMember2024-12-310001585364prgo:TrademarksTradeNamesAndBrandsMember2023-12-310001585364us-gaap:NoncompeteAgreementsMember2024-12-310001585364us-gaap:NoncompeteAgreementsMember2023-12-310001585364prgo:HospitalSpecialtyBusinessMember2024-01-012024-12-310001585364prgo:RareDiseasesBusinessMember2024-01-012024-12-3100015853642024-09-292024-12-310001585364us-gaap:LicensingAgreementsMember2024-01-012024-12-310001585364us-gaap:DevelopedTechnologyRightsMember2024-01-012024-12-310001585364us-gaap:CustomerRelationshipsMember2024-01-012024-12-310001585364prgo:TrademarksTradeNamesAndBrandsMember2024-01-012024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310001585364prgo:RareDiseasesReportingUnitMember2022-12-310001585364prgo:RareDiseasesReportingUnitMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberprgo:PublicBondsAndPrivatePlacementMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberprgo:PublicBondsAndPrivatePlacementMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberprgo:PublicBondsAndPrivatePlacementMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberprgo:PublicBondsAndPrivatePlacementMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberprgo:PublicBondsAndPrivatePlacementMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberprgo:PublicBondsAndPrivatePlacementMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberprgo:PublicBondsAndPrivatePlacementMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberprgo:PublicBondsAndPrivatePlacementMember2023-12-310001585364us-gaap:ForeignExchangeOptionMember2021-09-300001585364us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2021-09-300001585364us-gaap:ForeignExchangeOptionMember2022-04-300001585364us-gaap:ForeignExchangeOptionMember2022-04-012022-04-300001585364us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2022-01-012022-12-310001585364us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2021-01-012021-12-310001585364us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2024-01-012024-12-310001585364us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2023-01-012023-12-310001585364prgo:April142022ThroughApril202024Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-04-300001585364prgo:April272022ThroughMarch152026Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-04-300001585364prgo:April222022ThroughJune152030Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-04-300001585364us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-10-252022-10-250001585364prgo:October252022ThroughDecember152024Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-10-250001585364prgo:October252022ThroughMarch152026Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-10-250001585364prgo:October252022ThroughJune152030Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-10-250001585364prgo:November212023ThroughApril202027Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-11-210001585364us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-05-072024-05-070001585364prgo:May072024ThroughApril202027Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-05-070001585364us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-08-020001585364prgo:September172024ThroughSeptember302028Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-09-170001585364prgo:September172024ThroughJune152030Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-09-170001585364prgo:September172024ThroughSeptember302032Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-09-170001585364prgo:November212023ThroughApril202027Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-262024-11-260001585364prgo:May072024ThroughApril202027Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-262024-11-260001585364prgo:September172024ThroughSeptember302028Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-262024-11-260001585364prgo:October252022ThroughMarch152026Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-262024-11-260001585364us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-262024-11-260001585364prgo:September172024ThroughMarch302033Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-260001585364prgo:September172024ThroughDecember152030Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-260001585364prgo:October252022ThroughDecember152030Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-260001585364prgo:November272024ThroughApril202027Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-300001585364prgo:November272024ThroughSeptember302028Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-11-300001585364us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-12-310001585364prgo:EffectiveThroughMarch2026Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-12-310001585364prgo:EffectiveThroughApril2027Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-12-310001585364prgo:EffectiveThroughSeptember2028Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-12-310001585364prgo:EffectiveThroughDecember2030Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-12-310001585364prgo:EffectiveThroughMarch2033Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-12-310001585364us-gaap:InterestRateSwapMember2022-04-012022-04-300001585364prgo:TermLoanBFacilityMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-04-012022-04-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberprgo:TermLoanBMembersrt:MaximumMember2022-04-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberprgo:TermLoanBMembersrt:MinimumMember2022-04-300001585364prgo:TermLoanAFacilityMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-04-012022-04-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberprgo:TermLoanAMembersrt:MaximumMember2022-04-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberprgo:TermLoanAMembersrt:MinimumMember2022-04-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-11-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-11-012023-11-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-09-012024-09-300001585364prgo:DeDesignatedInterestRateSwapMember2024-09-012024-09-300001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-12-310001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-05-012024-05-310001585364us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-06-290001585364prgo:SeniorNotesDue2032Member2024-09-170001585364us-gaap:ForeignExchangeForwardMembersrt:MinimumMember2024-01-012024-12-310001585364us-gaap:ForeignExchangeForwardMembersrt:MaximumMember2024-01-012024-12-310001585364currency:EURus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:EURus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:GBPus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:GBPus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:SEKus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:SEKus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:USDus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:USDus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:CNYus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:CNYus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:CADus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:CADus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:DKKus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:DKKus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:NOKus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:NOKus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:HUFus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:HUFus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:PLNus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:PLNus-gaap:ForeignExchangeForwardMember2023-12-310001585364currency:XXXus-gaap:ForeignExchangeForwardMember2024-12-310001585364currency:XXXus-gaap:ForeignExchangeForwardMember2023-12-310001585364us-gaap:ForeignExchangeForwardMember2024-12-310001585364us-gaap:ForeignExchangeForwardMember2023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001585364us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-12-310001585364us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001585364us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-12-310001585364us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001585364us-gaap:DesignatedAsHedgingInstrumentMember2024-12-310001585364us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001585364us-gaap:NondesignatedMember2024-12-310001585364us-gaap:NondesignatedMember2023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2023-12-310001585364us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2024-12-310001585364us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2023-12-310001585364us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310001585364us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001585364us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310001585364us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherLiabilitiesMember2024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherLiabilitiesMember2023-12-310001585364us-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310001585364us-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-01-012024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:InterestExpenseMember2024-01-012024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:InterestExpenseMember2023-01-012023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:InterestExpenseMember2022-01-012022-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-12-310001585364us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-01-012022-12-310001585364us-gaap:InterestRateSwapMember2024-01-012024-12-310001585364us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-12-310001585364us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-12-310001585364us-gaap:CurrencySwapMember2024-01-012024-12-310001585364prgo:A5.375SeniorNotesDue2032Member2024-01-012024-12-310001585364us-gaap:TreasuryLockMember2023-01-012023-12-310001585364us-gaap:InterestRateSwapMember2023-01-012023-12-310001585364us-gaap:ForeignExchangeForwardMember2023-01-012023-12-310001585364us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-12-310001585364us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-12-310001585364us-gaap:CurrencySwapMember2023-01-012023-12-310001585364us-gaap:TreasuryLockMember2022-01-012022-12-310001585364us-gaap:InterestRateSwapMember2022-01-012022-12-310001585364us-gaap:ForeignExchangeForwardMember2022-01-012022-12-310001585364us-gaap:SalesMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-12-310001585364us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-12-310001585364us-gaap:CurrencySwapMember2022-01-012022-12-310001585364us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-12-310001585364us-gaap:SalesMemberus-gaap:InterestRateSwapMember2024-01-012024-12-310001585364us-gaap:CostOfSalesMemberus-gaap:InterestRateSwapMember2024-01-012024-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2024-01-012024-12-310001585364us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-12-310001585364us-gaap:SalesMemberus-gaap:TreasuryLockMember2023-01-012023-12-310001585364us-gaap:CostOfSalesMemberus-gaap:TreasuryLockMember2023-01-012023-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:TreasuryLockMember2023-01-012023-12-310001585364us-gaap:SalesMemberus-gaap:InterestRateSwapMember2023-01-012023-12-310001585364us-gaap:CostOfSalesMemberus-gaap:InterestRateSwapMember2023-01-012023-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2023-01-012023-12-310001585364us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-12-310001585364us-gaap:SalesMemberus-gaap:TreasuryLockMember2022-01-012022-12-310001585364us-gaap:CostOfSalesMemberus-gaap:TreasuryLockMember2022-01-012022-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:TreasuryLockMember2022-01-012022-12-310001585364us-gaap:SalesMemberus-gaap:InterestRateSwapMember2022-01-012022-12-310001585364us-gaap:CostOfSalesMemberus-gaap:InterestRateSwapMember2022-01-012022-12-310001585364us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2022-01-012022-12-310001585364prgo:TermALoansJune12022ThroughApril12027Member2024-12-310001585364prgo:TermALoansJune12022ThroughApril12027Member2023-12-310001585364prgo:TermBLoansJune12022ThroughApril12029Member2024-12-310001585364prgo:TermBLoansJune12022ThroughApril12029Member2023-12-310001585364prgo:A3.900SeniorNoteDue2024Member2024-12-310001585364prgo:A3.900SeniorNoteDue2024Member2023-12-310001585364prgo:A4.375SeniorNoteDueMarch152026Member2024-12-310001585364prgo:A4.375SeniorNoteDueMarch152026Member2023-12-310001585364prgo:SeniorNotesDueJune152030Member2024-12-310001585364prgo:SeniorNotesDueJune152030Member2023-12-310001585364prgo:A5.375SeniorNotesDue2032Member2024-12-310001585364prgo:A5.375SeniorNotesDue2032Member2023-12-310001585364prgo:A6.125SeniorNotesDue2032Member2024-12-310001585364prgo:A6.125SeniorNotesDue2032Member2023-12-310001585364prgo:A5.300SeniorNotesDue2043Member2024-12-310001585364prgo:A5.300SeniorNotesDue2043Member2023-12-310001585364prgo:A4.900SeniorNotesDue2044Member2024-12-310001585364prgo:A4.900SeniorNotesDue2044Member2023-12-310001585364prgo:SeniorNotesDueJune152030Member2024-06-150001585364prgo:SeniorNotesDueJune152030Member2024-06-160001585364us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310001585364us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-310001585364prgo:A2022RevolverMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-04-200001585364prgo:A2022RevolverMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-04-202022-04-200001585364prgo:TermLoanAFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-04-200001585364prgo:TermLoanAFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-04-202022-04-200001585364prgo:TermLoanBFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-04-200001585364prgo:TermLoanBFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-04-202022-04-200001585364prgo:TermLoanBFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-12-150001585364prgo:SeniorNotesDue2024Memberus-gaap:SeniorNotesMember2023-11-100001585364prgo:SeniorNotesDue2024Memberus-gaap:SeniorNotesMember2023-12-152023-12-150001585364us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-04-300001585364prgo:TermLoanAFacilityMember2023-01-012023-12-310001585364prgo:TermLoanBFacilityMember2023-01-012023-12-310001585364prgo:TermLoanBFacilityMember2024-09-192024-09-190001585364prgo:TermLoanBFacilityMember2024-06-302024-09-280001585364prgo:TermLoanBFacilityMemberus-gaap:SecuredDebtMember2024-12-152024-12-150001585364us-gaap:DomesticLineOfCreditMember2024-12-310001585364us-gaap:DomesticLineOfCreditMember2024-01-012024-12-310001585364prgo:A3.900SeniorNoteDue2024Memberus-gaap:SeniorNotesMember2014-12-020001585364prgo:A4.900SeniorNotesDue2044Memberus-gaap:SeniorNotesMember2014-12-020001585364prgo:SeniorNotes2014Memberus-gaap:SeniorNotesMember2014-12-022014-12-020001585364prgo:A4.900SeniorNotesDue2044Memberus-gaap:SeniorNotesMember2017-01-012017-12-310001585364prgo:A4.900SeniorNotesDue2044Memberus-gaap:SeniorNotesMember2017-12-310001585364prgo:A3.900SeniorNoteDue2024Memberus-gaap:SeniorNotesMember2023-12-150001585364prgo:A3.900SeniorNoteDue2024Memberus-gaap:SeniorNotesMember2023-12-152023-12-150001585364prgo:A3.900SeniorNoteDue2024Memberus-gaap:SeniorNotesMember2024-12-122024-12-120001585364prgo:A4.375SeniorNoteDueMarch152026Memberus-gaap:SeniorNotesMember2016-03-070001585364prgo:A4.375SeniorNoteDueMarch152026Memberus-gaap:SeniorNotesMember2016-03-072016-03-070001585364prgo:A4.375SeniorNoteDueMarch152026Memberus-gaap:SeniorNotesMember2024-09-292024-12-310001585364prgo:A3.150SeniorNotesDueJune152030Memberus-gaap:SeniorNotesMember2020-06-190001585364prgo:A3.150SeniorNotesDueJune152030Memberus-gaap:SeniorNotesMember2020-06-192020-06-190001585364prgo:A3.900SeniorNotesDueJune152030Memberus-gaap:SeniorNotesMember2021-12-150001585364prgo:A4.400SeniorNotesDueJune152030Memberus-gaap:SeniorNotesMember2022-06-150001585364prgo:A4650SeniorNotesDueJune152030Memberus-gaap:SeniorNotesMember2023-06-150001585364prgo:A4.900SeniorNotesDue2044Memberus-gaap:SeniorNotesMember2024-06-150001585364prgo:A6.125SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2024-09-170001585364prgo:A5.375SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2024-09-170001585364prgo:A6.125And5.375SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2024-09-170001585364prgo:A4.375SeniorNoteDueMarch152026Memberus-gaap:SeniorNotesMember2024-10-022024-10-020001585364prgo:A4.375SeniorNoteDueMarch152026Memberus-gaap:SeniorNotesMember2024-10-020001585364prgo:A5.300SeniorNotesDue2043Memberus-gaap:SeniorNotesMember2013-11-080001585364prgo:A5.300SeniorNotesDue2043Memberus-gaap:SeniorNotesMember2017-01-012017-12-310001585364country:US2024-01-012024-12-310001585364country:IE2024-01-012024-12-310001585364us-gaap:DefinedBenefitPostretirementHealthCoverageMember2024-01-012024-12-310001585364us-gaap:PensionPlansDefinedBenefitMember2023-12-310001585364us-gaap:PensionPlansDefinedBenefitMember2022-12-310001585364us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001585364us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310001585364us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310001585364us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001585364us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310001585364us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310001585364us-gaap:PensionPlansDefinedBenefitMember2024-12-310001585364us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310001585364us-gaap:OtherNoncurrentAssetsMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310001585364us-gaap:OtherNoncurrentAssetsMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001585364us-gaap:OtherNoncurrentAssetsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310001585364us-gaap:OtherNoncurrentAssetsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001585364us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310001585364us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001585364us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310001585364us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001585364us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001585364us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310001585364us-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2024-01-012024-12-310001585364us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMember2024-01-012024-12-310001585364us-gaap:PensionPlansDefinedBenefitMemberprgo:AbsoluteReturnFundMember2024-01-012024-12-310001585364us-gaap:PensionPlansDefinedBenefitMemberus-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2024-01-012024-12-310001585364us-gaap:PensionPlansDefinedBenefitMemberprgo:OtherMember2024-01-012024-12-310001585364srt:MinimumMemberus-gaap:EquitySecuritiesMember2024-12-310001585364srt:MaximumMemberus-gaap:EquitySecuritiesMember2024-12-310001585364srt:MinimumMemberus-gaap:DebtSecuritiesMember2024-12-310001585364srt:MaximumMemberus-gaap:DebtSecuritiesMember2024-12-310001585364srt:MinimumMemberprgo:AbsoluteReturnFundMember2024-12-310001585364srt:MaximumMemberprgo:AbsoluteReturnFundMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2024-12-310001585364us-gaap:EquitySecuritiesMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2023-12-310001585364us-gaap:EquitySecuritiesMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2024-12-310001585364us-gaap:DebtSecuritiesMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2023-12-310001585364us-gaap:DebtSecuritiesMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2024-12-310001585364us-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2023-12-310001585364us-gaap:InsuranceContractRightsAndObligationsFairValueOptionMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberprgo:AbsoluteReturnFundMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberprgo:AbsoluteReturnFundMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberprgo:AbsoluteReturnFundMember2024-12-310001585364prgo:AbsoluteReturnFundMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberprgo:AbsoluteReturnFundMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberprgo:AbsoluteReturnFundMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberprgo:AbsoluteReturnFundMember2023-12-310001585364prgo:AbsoluteReturnFundMember2023-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2024-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2024-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMember2024-12-310001585364us-gaap:CashAndCashEquivalentsMember2024-12-310001585364us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2023-12-310001585364us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2023-12-310001585364us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMember2023-12-310001585364us-gaap:CashAndCashEquivalentsMember2023-12-310001585364us-gaap:FairValueInputsLevel1Member2024-12-310001585364us-gaap:FairValueInputsLevel2Member2024-12-310001585364us-gaap:FairValueInputsLevel3Member2024-12-310001585364us-gaap:FairValueInputsLevel1Member2023-12-310001585364us-gaap:FairValueInputsLevel2Member2023-12-310001585364us-gaap:FairValueInputsLevel3Member2023-12-310001585364us-gaap:FairValueInputsLevel3Member2022-12-310001585364us-gaap:FairValueInputsLevel3Member2024-01-012024-12-310001585364us-gaap:FairValueInputsLevel3Member2023-01-012023-12-310001585364us-gaap:DeferredCompensationArrangementWithIndividualByTypeOfCompensationPensionAndOtherPostretirementBenefitsMember2024-12-310001585364us-gaap:DeferredCompensationArrangementWithIndividualByTypeOfCompensationPensionAndOtherPostretirementBenefitsMember2023-12-3100015853642018-10-310001585364srt:MinimumMember2024-01-012024-12-310001585364srt:MaximumMember2024-01-012024-12-310001585364prgo:ServiceBasedRestrictedShareUnitsMember2022-12-310001585364prgo:ServiceBasedRestrictedShareUnitsMember2022-01-012022-12-310001585364prgo:ServiceBasedRestrictedShareUnitsMember2023-01-012023-12-310001585364prgo:ServiceBasedRestrictedShareUnitsMember2023-12-310001585364prgo:ServiceBasedRestrictedShareUnitsMember2024-01-012024-12-310001585364prgo:ServiceBasedRestrictedShareUnitsMember2024-12-310001585364prgo:PerformanceBasedRestrictedShareUnitsMember2022-12-310001585364prgo:PerformanceBasedRestrictedShareUnitsMember2022-01-012022-12-310001585364prgo:PerformanceBasedRestrictedShareUnitsMember2023-01-012023-12-310001585364prgo:PerformanceBasedRestrictedShareUnitsMember2023-12-310001585364prgo:PerformanceBasedRestrictedShareUnitsMember2024-01-012024-12-310001585364prgo:PerformanceBasedRestrictedShareUnitsMember2024-12-310001585364prgo:RelativeTotalShareholderReturnPerformanceShareUnitsMember2024-01-012024-12-310001585364prgo:RelativeTotalShareholderReturnPerformanceShareUnitsMember2023-01-012023-12-310001585364prgo:RelativeTotalShareholderReturnPerformanceShareUnitsMember2022-01-012022-12-310001585364prgo:RelativeTotalShareholderReturnPerformanceShareUnitsMember2022-12-310001585364prgo:RelativeTotalShareholderReturnPerformanceShareUnitsMember2023-12-310001585364prgo:RelativeTotalShareholderReturnPerformanceShareUnitsMember2024-12-310001585364us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001585364us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001585364us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001585364us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001585364us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310001585364us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310001585364us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001585364us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001585364us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001585364us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310001585364us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-310001585364us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310001585364us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310001585364us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001585364us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310001585364prgo:SupplyChainReinventionMember2023-12-310001585364prgo:HRAPharmaIntegrationMember2023-12-310001585364prgo:ProjectEnergizeMember2023-12-310001585364us-gaap:OtherRestructuringMember2023-12-310001585364prgo:SupplyChainReinventionMember2024-01-012024-12-310001585364prgo:HRAPharmaIntegrationMember2024-01-012024-12-310001585364prgo:ProjectEnergizeMember2024-01-012024-12-310001585364us-gaap:OtherRestructuringMember2024-01-012024-12-310001585364prgo:SupplyChainReinventionMember2024-12-310001585364prgo:HRAPharmaIntegrationMember2024-12-310001585364prgo:ProjectEnergizeMember2024-12-310001585364us-gaap:OtherRestructuringMember2024-12-310001585364prgo:SupplyChainReinventionMember2022-12-310001585364prgo:HRAPharmaIntegrationMember2022-12-310001585364prgo:ProjectEnergizeMember2022-12-310001585364us-gaap:OtherRestructuringMember2022-12-310001585364prgo:SupplyChainReinventionMember2023-01-012023-12-310001585364prgo:HRAPharmaIntegrationMember2023-01-012023-12-310001585364prgo:ProjectEnergizeMember2023-01-012023-12-310001585364us-gaap:OtherRestructuringMember2023-01-012023-12-310001585364prgo:SupplyChainReinventionMember2021-12-310001585364prgo:HRAPharmaIntegrationAndOtherRestructuringMember2021-12-310001585364prgo:SupplyChainReinventionMember2022-01-012022-12-310001585364prgo:HRAPharmaIntegrationAndOtherRestructuringMember2022-01-012022-12-310001585364prgo:HRAPharmaIntegrationAndOtherRestructuringMember2022-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareInternationalMember2024-01-012024-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareAmericasMember2024-01-012024-12-310001585364us-gaap:MaterialReconcilingItemsMember2024-01-012024-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareInternationalMember2023-01-012023-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareAmericasMember2023-01-012023-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareInternationalMember2022-01-012022-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareAmericasMember2022-01-012022-12-3100015853642009-01-012009-12-3100015853642010-01-012010-12-3100015853642011-01-012011-12-3100015853642012-01-012012-12-3100015853642017-08-152017-08-1500015853642021-01-132021-01-130001585364srt:MinimumMember2021-01-132021-01-130001585364srt:MaximumMember2021-01-132021-01-1300015853642021-01-130001585364prgo:GenericPricingMultidistrictLitigationMember2024-12-310001585364prgo:StateAttorneyGeneralComplaintMember2020-06-100001585364prgo:CanadianClassActionComplaintMember2020-06-300001585364prgo:HospitalComplaintMember2023-06-300001585364prgo:SelfInsuredEmployerComplaintMember2024-04-042024-04-040001585364prgo:SelfInsuredEmployerComplaintMember2024-04-0400015853642017-06-210001585364prgo:SecuritiesLitigationInTheUnitedStatesMember2017-06-210001585364prgo:SecuritiesLitigationInTheUnitedStatesMember2019-11-140001585364prgo:SecuritiesLitigationInTheUnitedStatesMember2024-04-052024-04-050001585364prgo:SecuritiesLitigationInTheUnitedStatesMember2024-01-012024-03-300001585364prgo:SecuritiesLitigationInTheUnitedStatesMember2024-05-012024-05-310001585364prgo:SecuritiesLitigationInTheUnitedStatesMember2024-01-012024-12-310001585364prgo:SecuritiesLitigationInTheUnitedStatesMember2020-06-012020-06-300001585364prgo:SecuritiesLitigationInTheUnitedStatesMemberus-gaap:SubsequentEventMember2025-01-012025-01-310001585364prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member2017-06-280001585364prgo:IsraelElec.Corp.EmployeesEduc.Fundv.PerrigoCompanyplcetal.Member2017-06-282017-06-280001585364prgo:TalcumPowderLitigationMemberus-gaap:SubsequentEventMember2025-02-280001585364prgo:RanitidineLitigationMember2024-12-310001585364prgo:InsuranceCoverageLitigationMember2021-05-310001585364us-gaap:MaterialReconcilingItemsMember2023-01-012023-12-310001585364us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareAmericasMember2022-12-310001585364us-gaap:OperatingSegmentsMemberprgo:ConsumerSelfCareInternationalMember2022-12-310001585364us-gaap:MaterialReconcilingItemsMember2022-12-310001585364country:US2024-12-310001585364country:US2023-12-310001585364srt:EuropeMember2024-12-310001585364srt:EuropeMember2023-12-310001585364prgo:AllOtherCountriesMember2024-12-310001585364prgo:AllOtherCountriesMember2023-12-310001585364country:IE2024-12-310001585364country:IE2023-12-310001585364prgo:WalmartMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310001585364prgo:WalmartMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310001585364prgo:WalmartMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-31

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2024

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 001-36353

(Exact name of registrant as specified in its charter)

Securities registered pursuant to Section 12(b) of the Act:

Securities registered pursuant to Section 12(g) of the Act: None

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes

☒

No

☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 of Section 15(d) of the Act.

Yes

☐

No

☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

☒

No

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

☒

No

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.

☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes

☐

No

☒

The aggregate market value of the voting stock held by non-affiliates of the registrant, based upon the closing sale price of our ordinary shares on June 28, 2024 as reported on the New York Stock Exchange, was $3,502,398,592. Ordinary shares held by each director or executive officer have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

As of February 21, 2025, the registrant had 136,458,620 outstanding ordinary shares.

Documents incorporated by reference:

The information called for by Part III will be incorporated by reference from the Registrant's definitive Proxy Statement for its Annual Meeting of Shareholders to be filed pursuant to Regulation 14A or will be included in an amendment to this Form 10-K.

TABLE OF CONTENTS

						Page No.
Cautionary Note Regarding Forward-Looking Statements						3
Part I.
Item 1.			Business			4
Item 1A.			Risk Factors			15
Item 1B.			Unresolved Staff Comments			32
Item 1C.			Cybersecurity			33
Item 2.			Properties			34
Item 3.			Legal Proceedings			35
Item 4.			Mine Safety Disclosures			35
Additional Item.			Information About Our Executive Officers			35
Part II.
Item 5.			Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities			36
Item 6.			[Reserved]			36
Item 7.			Management’s Discussion and Analysis of Financial Condition and Results of Operations			37
Item 7A.			Quantitative and Qualitative Disclosures About Market Risk			54
Item 8.			Financial Statements and Supplementary Data			56
Item 9.			Changes in and Disagreements With Accountants on Accounting and Financial Disclosure			121
Item 9A.			Controls and Procedures			121
Item 9B.			Other Information			121
Item 9C.			Disclosure Regarding Foreign Jurisdictions that Prevent Inspections			121
Part III.
Item 10.			Directors, Executive Officers and Corporate Governance			121
Item 11.			Executive Compensation			122
Item 12.			Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters			122
Item 13.			Certain Relationships and Related Transactions, and Director Independence			122
Item 14.			Principal Accounting Fees and Services			122
Part IV.
Item 15.			Exhibits and Financial Statement Schedules			123

Certain statements in this report are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” "forecast," “predict,” “potential” or the negative of those terms or other comparable terminology.

The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including: supply chain impacts on the Company’s business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business, including the Middle East; current and future impairment charges, including those related to the sale of the Héra SAS ("HRA Pharma") Rare Diseases Business, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding the Company's ability to obtain and maintain its regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; the Company’s ability to achieve benefits expected from its sale of the HRA Rare Diseases Business, including potential earnout payments, and the sale of its Hospital and Specialty Business and the risk that potential costs or liabilities incurred or retained in connection with those transactions may exceed the Company's estimates or adversely affect the Company's business or operations; the risk that potential costs or liabilities incurred or retained in connection with the sale of the Company's Rx business may exceed the Company’s estimates or adversely affect the Company’s business or operations; the Company's ability to achieve the benefits expected from the acquisitions of HRA Pharma and Nestlé’s Gateway infant formula plant along with the U.S. and Canadian rights to the GoodStart® infant formula brand and other related formula brands ("Gateway") and/or the risks that the Company’s synergy estimates are inaccurate or that the Company faces higher than anticipated integration or other costs in connection with the acquisitions; risks associated with the integration of HRA Pharma and Gateway, including the risk that growth rates are adversely affected by any delay in the integration of sales and distribution networks; the consummation and success of other announced and unannounced acquisitions or dispositions, and the Company’s ability to realize the desired benefits thereof; and the Company’s ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including the Company's ability to achieve the expected benefits from its ongoing restructuring programs described herein. Adverse results with respect to pending litigation could have a material adverse impact on the Company's operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in this report under “Risk Factors” and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this report are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

This report contains trademarks, trade names and service marks that are the property of Perrigo Company plc, as well as, for informational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, certain trademarks, trade names, and service marks referred to in this report appear without the ®, ™ and SM symbols, but those references are not intended to indicate that we or the applicable owner, as the case may be, will not assert, to the fullest extent under applicable law, our or their rights to such trademarks, trade names, and service marks.

The Company’s plan to drive cash flow and total shareholder return is anchored behind its ‘Three-S’ plan – ‘Stabilizing’ Consumer Self-Care Americas store brand and infant formula businesses; ‘Streamlining’ the global portfolio, enterprise operating model and Consumer Self-Care International business; and ‘Strengthening’ what is working by prioritizing and increasing investments behind key ‘High-Grow’ brands. Further 2024 highlights can be found in Item 7. Management Discussion and Analysis - Executive Overview.

Our objective is to grow our business by responsibly leveraging our global infrastructure to deliver high quality self-care solutions to customers and consumers through our expansive product offerings, providing new innovative products, brands, and product line extensions to existing consumers and servicing new consumers through entering new adjacent products and categories, new geographies and new channels of distribution organically and inorganically.

Among other things, we believe the following factors give us a competitive advantage and provide value to our customers and consumers:

•A diverse product portfolio, leadership in first-to-market product development, and product life cycle management;

•Experienced research and development ("R&D"), innovation and regulatory capabilities to develop and launch high-quality solutions, differentiated product features and benefits, product reformulations, new brands and brand line extensions, and differentiated products;

•Deep understanding of consumer needs and customer strategies with market, category and product specific promotional and e-commerce capabilities;

•Expansive pan-European commercial infrastructure, brand-building capabilities, and an extensive and diverse product portfolio;

•Supply chain breadth, and utilizing economies of scale to manage supply chain complexity across multiple dosage forms, formulations, and stock-keeping units; and

•Quality and cost effectiveness throughout the supply chain and operational systems across all products creating a sustainable, lower-cost network across our manufacturing and distribution networks.

•Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business in the U.S. and Canada.

•Consumer Self-Care International ("CSCI") comprises our consumer self-care business outside of the U.S. and Canada, primarily in Europe and Australia.

We previously had an Rx segment comprised of our generic prescription pharmaceuticals business in the U.S. and other pharmaceuticals and diagnostic businesses in Israel, which have been divested. The Rx segment was reported as Discontinued Operations in 2021, and is presented as such for all periods in this report. See Item 8. Note 4 for more information. Financial information related to our business segments can be found in Item 8. Note 20.

The CSCA segment develops, manufactures and markets our leading self-care consumer solutions in the U.S. and Canada. We primarily provide our customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands ("store brands"). We additionally have a select lineup of branded self-care products. Customers include major global, national, and regional retail drug, supermarket, mass merchandise chains, e-commerce retailers, and major wholesalers.

Our store brand products are comparable in quality and effectiveness to national brands. Store brand products must meet the same stringent U.S. Food and Drug Administration ("FDA") requirements as national brands within the U.S. and the requirements of comparable regulatory bodies outside the U.S. In most instances, our product packaging, marketing, advertising, and e-commerce focus are designed to invite and reinforce comparison to national brand products, while conveying a superior value for consumers. The cost of store brand products to retailers is significantly lower than that of comparable nationally advertised brand name products. The retailer, therefore, can price a store brand product below the competing national brand product and realize a greater percentage and dollar profit, while consumers benefit from receiving a high-quality product at a price below the comparable national brand product. Consumer awareness and knowledge of the quality, value and efficacy of our products are achieved from marketing efforts made by us, our retailer customers and wholesalers.

Certain branded products are developed, manufactured and distributed within the CSCA segment. Our primary branded products sold under brand names include Compeed®, Dr. Fresh®, Firefly®, Good Sense®, Good Start®, Mederma®, Nasonex®, Plackers®, Prevacid®24HR, REACH®, Rembrandt®, Steripod®. In March 2024, we launched Opill®, the first ever FDA approved birth control pill for OTC use without age restriction. On September 26, 2024, we announced a new brand partnership with Dr. Brown's™ Baby to provide infant formula solutions for babies with tolerance concerns. The new Good Start® | Dr. Brown's™ portfolio will offer the same trusted infant formula products as the existing SoothePro™ and GentlePro™, continue to feature probiotics, advanced protein hydrolysis, and 100% whey protein; but now with a refreshed label to celebrate the new partnership.

The CSCI segment comprises our consumer self-care product categories outside the U.S. and Canada, including our branded products in Europe and Australia and our store brand products in the United Kingdom and parts of Europe and Asia.

We leverage our broad marketing, sales, regulatory, manufacturing and distribution infrastructure to drive market share, innovate new products and brands, in-license and expand product lines, and sell and distribute third-party brands. The CSCI segment products are sold primarily through an established pharmacy sales force to an extensive network of customers including pharmacies, wholesalers, drug and grocery store retailers, e-commerce retailers, and para-pharmacies in more than 31 countries, predominantly in Europe. Products in the CSCI segment are marketed using traditional and digital advertising as well as point-of-sale promotional spending to enhance brand equity.

While we have hundreds of brands, we focus our resources on growth brands, including Solpadeine®, Coldrex®, Physiomer®, NiQuitin®, ACO®, Compeed®, and ellaOne®. Many of these brands have leading positions in the markets in which they compete. Additional resources, including R&D investments, are allocated to these brands to strengthen their market position while leveraging the same R&D efforts under smaller local brands. Our new product pipeline is supported by internal R&D, new product development, acquisitions and partnerships, both in terms of brand extensions and product improvements.

We offer products in the following categories:

(1) The Nutrition product category is exclusive to CSCA. During 2023 we exited the nutritional beverages product line.

(2) Rare Diseases Business within the Other product category is exclusive to CSCI. During 2024 we divested the Rare Diseases Business. Refer to Item 8. Note 3.

In April 2022, we completed the acquisition of HRA Pharma for €1.8 billion, or approximately $1.9 billion based on exchange rates at the time of closing (refer to Item 8. Note 3 for transaction details). HRA Pharma operating results are reported within both our CSCA and CSCI segments. As a result of the acquisition, the Company made the following updates to its global reporting product categories described above:

•The creation of a new "Women's Health" reporting category, comprised of the women's health portfolio of HRA Pharma, including ellaOne® and Hana®, in addition to legacy Perrigo women's health products, including feminine hygiene and contraceptive products;

•The creation of a new "Skin Care" reporting category, comprised of Compeed®, Mederma®, and all of the products in the legacy Perrigo "Skincare and Personal Hygiene" category except for legacy Perrigo women's health products; and

•The "Other" category includes the Rare Diseases Business acquired with HRA Pharma exclusive to the CSCI segment and other miscellaneous self-care products in CSCA. During 2024, we completed the sale of the Rare Diseases Business (refer to Item 8. Note 3 for transaction details).

The updates were applied retroactively to impacted product categories. Such changes had no impact on the Company's historical consolidated financial position, results of operations or cash flows.

We consider a product to be new if it (i) was reformulated into an additional unique product, (ii) was a product line extension due to changes in characteristics such as strength, flavor, or color, (iii) had a change in product status from "prescription only" ("Rx") to OTC, (iv) was a new store brand or branded launch, (v) was provided in a new dosage form or (vi) was sold to a new geographic area with different regulatory authorities, in all cases, within 12 months prior to the end of the period for which net sales are being measured.

Notable new product launches in the year ended December 31, 2024 included Opill® in CSCA Women's Health category and various CSCI line extensions in the Bronchostop® cough brand in the Upper Respiratory category and ACO® and Compeed® bundles within the Skin Care category.

On March 4, 2024, we announced that Opill® began shipments to major retailers and pharmacies and was available on shelves nationwide and online later that month. Approved by the FDA for OTC use without age restriction in July 2023, Opill® is the first-ever daily birth control pill available without a prescription in the U.S.

Each of our product categories and growth brands have a three to five-year innovation master plan. We rely on both internal R&D and strategic product development agreements with outside sources to develop new products.

    

Sales to Walmart Inc. represented 11.9% and 11.8% of our consolidated net sales in 2024 and 2023, respectively. While we have other important customers, no other individual customer represents more than 10% of net sales. Our top ten customers accounted for 46% of our total consolidated net sales in 2024 and 2023. We believe we generally have good relationships with our customers. Refer to Item 1A. Risk Factors - Operational Risks for risks associated with customers.

The markets for our self-care products are highly competitive and differ for each product line, category and geographic region. Local companies often hold leading positions in individual product lines in particular countries. The competitive landscape of the European consumer products market in the categories in which we compete is more fragmented than the North American market. Our primary competitors include manufacturers, such as Dr. Reddy's Labs, LNK International, Inc., PL Developments, Aurobindo and Sun Pharmaceuticals, and brand-name pharmaceutical and consumer product companies, such as Haleon, Kenvue, Procter & Gamble, Reckitt Benckiser, Abbott Nutrition, Bayer AG, Opella, Philips, Teva, Viatris, and Stada. Each product category of our business has certain key competitors, such that a competitor generally does not compete across all product lines or across all geographic markets. However, some competitors do have larger sales volumes in certain of our categories. Competition is based on a variety of factors, including price, quality, product assortment, customer service, marketing support and approvals for new products. Refer to Item 1A. Risk Factors - Operational Risks for additional information and risks associated with competition.

While we own certain trademarks and patents, neither our business as a whole, nor any of our segments, is materially dependent upon our ownership of any one trademark, or patent, or group of trademarks or patents.

Low cost, high-quality raw materials and packaging components are essential to all of our business units. Raw materials and packaging components are generally available from multiple suppliers. Supplies of certain raw materials and packaging components, due to their technical specifications and product delivery systems, may be more limited, as they may be available from one or only a few suppliers and may require extensive compatibility testing before we can use them.

Historically, we have been able to react effectively, yet not always immediately, to situations that require alternate sourcing. Should such alternate sourcing be necessary, FDA requirements placed on products approved through the Abbreviated New Drug Application ("ANDA") or New Drug Application ("NDA") process could substantially lengthen the approval of an alternate source and adversely affect financial results. We believe we have good, cooperative working relationships with our suppliers and have historically been able to capitalize on economies of scale in the purchase of materials and supplies due to our volume of purchases. Refer to Item 1A. Risk Factors - Operational Risks for risks associated with materials sourcing. Refer to Item 7. Management's Discussion and Analysis - Executive Overview for a detailed discussion of the impact of inflation and supply chain disruptions, the war in Ukraine, and the Middle East conflicts on our materials sourcing.

Our primary manufacturing facilities are in the U.S. We also have manufacturing facilities in the U.K., Belgium, France, Germany, Austria, and China, along with a joint venture in China. We supplement our production capabilities with the purchase of products from external sources.

While our business is not generally seasonal, the capacity of some facilities may not be fully utilized at certain times for various reasons, such as consumer and customer demand, the seasonality of certain product categories (for example, cough/cold/flu and allergy products) and new product launches. We may utilize available capacity by performing contract manufacturing for other companies. We have logistics facilities in the U.S., numerous locations throughout Europe, and Australia. We use contract freight and common carriers to deliver our products to customers. We also utilize direct-to-consumer platforms to deliver certain offerings to consumers.

In 2022, we initiated a Supply Chain Reinvention Program to reduce structural costs, improve profitability and our service levels to our retail partners, and strengthen our resiliency by streamlining and simplifying our global supply chain. Through this initiative, we are reducing portfolio complexity, investing in advanced planning capabilities, diversifying sourcing, and optimizing our manufacturing assets and distribution models.

Refer to Item 7. Management's Discussion and Analysis - Executive Overview for a detailed discussion of the impact of inflation and supply chain disruption, and the Supply Chain Reinvention Program on our manufacturing and distribution, and refer to Item 1A. Risk Factors - Operational Risks for risks associated with our manufacturing facilities.

The core of Perrigo's business is empowering people to own and manage their self-care through high-quality and widely accessible products. We push the boundaries of innovation, refining our business and products to provide the best self-care for everyone. That means we lead with an innovative spirit and relentless dedication to excellence - from product development to managing environmental and social challenges. Our experience shows that embedding sustainability into our business practices creates opportunities for growth and impact-driven value creation.

Each year, we publish our annual Sustainability Report to transparently disclose our progress against our sustainable business and corporate commitments. This report details the comprehensive set of metrics we use to track our targets. The report also includes appendices informed by the following frameworks:

•The Global Reporting Initiative ("GRI")

•Sustainability Accounting Standards Board ("SASB")

•United Nations Sustainable Development Goals

Our latest Sustainability Report for fiscal year 2024 is available on our website at www.perrigo.com. Detailed information about our performance against our climate goals is available through our annual CDP disclosure. References to our reports and the website are for informational purposes only, and neither the Sustainability Report nor the other information on our website is incorporated by reference into this Annual Report on Form 10-K.

Perrigo's sustainability strategy focuses on our four core sustainability business priorities: Climate, Packaging, People & Communities and Responsible Sourcing. These focus areas reflect our dedication to mitigating the impacts of our business. Accordingly, we have established 10 goals with complementary metrics to measure our progress along the way. While some of these goals are aspirational in nature, such as becoming NetZero by 2040, the majority are measured as annual performance indicators.

Acting on Climate: Mitigating the climate crisis requires ambitious goals and credible, science-based actions. Perrigo's goal is to reach net zero greenhouse gas emissions across our supply chain and operations by 2040. Our plan involves reducing our direct and indirect emissions by minimizing our production footprint, buying renewable energy, redesigning our products and packaging, and switching to electric vehicle fleets for our international business.

People & Communities: We are dedicated to promoting a culture of inclusivity and teamwork in the workplace and in the communities around us. In recent years, Perrigo has made significant progress in reflecting the experiences of the consumers we serve, including increasing representation at our organization's board and executive levels.

Reduce and Redesign Waste & Packaging: Better products and packaging help our consumers, the climate, and our planet. We are contributing to the circular economy by transitioning to reusable, recyclable, and compostable packaging, where possible. Our priorities include reducing packaging weight and innovating materials.

Responsible Sourcing: We are committed to upholding human rights, ensuring fair working conditions, and protecting the environment in our supply chain. We ensure our strong dedication to upholding human rights and environmental standards by implementing rigorous monitoring programs.

Our intention is to collaborate with suppliers who share our values and responsible practices to make a positive impact on our value chain.

Our facilities and operations are subject to various environmental laws and regulations relating to air emissions, wastewater discharges, solid and hazardous waste management activities, and the safety of our employees. We undergo periodic internal audits related to environmental, health, and safety requirements to maintain compliance with applicable laws and regulations in each jurisdiction where we operate. We also maintain regulatory registers of all applicable environmental, health and safety compliance obligations that we conduct periodic self-assessments against to determine our compliance status for each manufacturing site. We have made, and continue to make, expenditures necessary to comply with applicable environmental laws; however, we do not believe that the costs for complying with such laws and regulations have been or will be material to our business. We do not have any material remediation liabilities outstanding.

As part of our climate strategy, we're in the process of integrating transitional and physical climate risks into our business strategy and disclosure efforts. We recognize that climate risks may pose potential threats but also offer long term opportunities. We are dedicated to advancing the tools and methodologies for assessing climate impacts, tracking progress in reducing greenhouse gas emissions, and evaluating potential climate-driven risks to our business strategy.

We believe that the support and development of our global colleagues is an important component enabling us to attract, retain, and engage the talent needed to deliver on our self-care strategy. Our global workforce consists of 8,379 full-time and part-time employees spread across 33 countries, of which approximately 20% were covered by collective agreements as of December 31, 2024. We continuously endeavor to provide a safe and inclusive work environment so our colleagues can bring their best to work every day. Our vision is clear: “To Provide the Best Self-Care for Everyone”. And at Perrigo, our success is not just about reaching these goals; it is about how we get there. The way we work together is foundational. Our Core Values ensure that every decision we each make supports our vision and strengthen our collective impact as One Perrigo. Each global colleague is responsible for upholding Perrigo’s three Core Values of: We Care Deeply, We Do the Right Thing and We Play to Win.

Consistent with our Vision, and Core Values, we strive for a world-class and representative workforce that reflects our consumers across the globe, enabling us to continue to provide the best self-care to everyone. We believe that equitable practices and fostering an environment where every individual feels valued, respected and empowered at work creates lasting benefits for our colleagues, customers, consumers, and shareholders and enhances our culture, performance, and profitable growth. Our strategy focuses on building a winning culture through 'belonging' by:

•Educating our workforce to create an environment where every individual feels valued, respected and empowered at work;

•Strengthening our talent management practices through a lens of equity and belonging; and

•Enabling leaders, embedding accountability and strengthening our governance practices.

We are committed to making self-care accessible to all and understand that we can accomplish this by nurturing a culture of belonging where people feel valued, welcomed, respected and heard. Achieving this goal enables our colleagues to deliver their best work and keep our consumers at the center of how we innovate, create, and deliver results. Accordingly, we continue to take action to help ensure our practices, policies, and processes are inclusive and equitable for all colleagues. We also strive to support the well-being of the communities we serve and the individuals that make up our team of talented colleagues.

Colleagues at all levels of our Company continually receive educational resources and information on how to best support themselves and foster a culture where every individual feels supported and respected for who they are. Colleagues are encouraged to practice self-care and are provided support resources such as our global Employee Assistance Program which is designed to meet diverse needs of our colleagues across multiple identities, cultures and languages.

Perrigo’s commitment to self-care starts with our own team. We are dedicated to maintaining a safe workplace for our team members. As a multi-national company, we are subject to a broad range of local and international laws and regulations relating to occupational safety and health, and our safety program is designed to meet these compliance requirements at a minimum. We also set specific safety standards to proactively identify and manage critical risks to eliminate significant injury and fatality potential in our operations. We continuously evaluate all applicable opportunities to reduce risk and provide a safe secure environment and our goal is to create a 100% safe workplace for our team members.

Our Total Rewards philosophy is to continuously attract, engage and inspire our people by designing Total Rewards that reinforce 'belonging' at Perrigo and align with our values and winning culture, helping to drive top tier performance and fulfill Perrigo's Vision. Our Total Rewards package delivers competitive pay, cash-based incentives, broad-based stock grants, retirement benefits, leading healthcare, paid time off, and on-site wellness services, among other benefits. Additionally, we are proud to continue our “HEALTHYyou” well-being program that supports our colleagues and their families in maintaining and improving their health as they navigate their own self-care and well-being journeys. This program is highly valued by our colleagues and it continues to be recognized externally by receiving the Best and Brightest in Wellness™ Award every year since 2017.

The main ambition of our One Perrigo culture is to unlock the potential of our organization and our people. It will improve our ability to anticipate and create globally consistent and competitive organizational capabilities, attractive career opportunities, challenging work and personal growth. As Perrigo grows, we want to ensure our people grow with it.

In addition to redefining our vision, we have also defined core behaviors that describe “Perrigo at our Best”. These are a globally consistent set of behaviors describing what good looks like, with 5 developmental levels associated with each behavior. Our core behaviors will strengthen our culture, create better clarity on where employees are on their development journey, enable higher quality feedback, establish clear indicators of progression to the next level to simplify and accelerate career development. The core behaviors create a transparent and objective data-driven approach ensuring our hiring, onboarding and development processes are equitable.

Our philosophy in development is a partnership between our colleagues and their managers. We encourage and support our managers to hold annual career development conversations with their team. We have a robust annual process in place to identify talent and match them with the right opportunities to engage and develop them.

We also empower colleagues to take control of their own development by providing access to our 'GROWyou' personal development curriculum. This curriculum is supplemented by offering colleagues 24/7 access to on-demand self-study content. Personal development and learning are guided by ongoing conversations and feedback as part of our performance management philosophy.

We continue to invest in our leadership capability at all levels in the organization so they can provide the right environment within our culture to engage, grow and develop our colleagues.

We also want to ensure that colleagues can connect their daily work to our vision, purpose and strategy. We do this through regular global, functional and local townhalls and regular round table discussions with senior leaders. This gives colleagues an opportunity to stay up to date, share their views and to get their questions answered. We also run regular engagement surveys to take feedback from the organization and convert that feedback into meaningful action to build a winning culture.

Perrigo is committed to the fight against modern slavery, child labor, unsafe working conditions and any other form of Human Rights abuse. We maintain a robust set of ethical standards that apply to all of Perrigo globally, as well as any contractors, suppliers, and other third parties doing business on our behalf. We conduct regular risk assessments and audits of our supply chain to ensure compliance with our internal standards and those of our customers.

The Perrigo Company Charitable Foundation (the "Foundation") exists to support nonprofit organizations' initiatives in health and self-care, education, and community engagement and well-being within the communities where Perrigo operates around the world, mainly through a grant application process.

The Foundation provides opportunities for our employees to get involved and give back their time and talent through charitable work and programs that put additional funds into the hands of those who need them most. We encourage all employees to volunteer in their local communities, which we believe has additional benefits on morale, mental health and goodwill as well as professional skills and network development.

More details on these and other Perrigo Company initiatives are available on our website at www.perrigo.com.

The manufacturing, processing, formulation, packaging, labeling, testing, storing, distributing, advertising, and selling of our products are subject to regulation by a variety of agencies in the localities in which our products are sold. In addition, we manufacture and market certain of our products in accordance with standards set by various organizations. We believe that our policies, operations, and products comply in all material respects with existing regulations to which we are subject. Refer to Item 1A. Risk Factors - Operational Risks for related risks.

Under the Federal Food, Drug and Cosmetic Act, as amended ("FDCA") the FDA has jurisdiction over OTC drug products, Active Pharmaceutical Ingredients ("API"), medical devices, cosmetics, and foods including dietary supplements and infant formula products. The FDA’s jurisdiction can include the sourcing, manufacturing, testing, labeling, packaging, storage, distribution and marketing of these products. We are committed to consistently providing our customers with high quality products that adhere to FDA recommendations in industry guidance and meet the requirements of various regulations promulgated by the FDA. The FDA conducts periodic compliance inspections of our facilities, quality management system and manufacturing processes. If the FDA or comparable regulatory authority becomes aware of new safety information about any of our products, these authorities may require further inspection, enhancement to manufacturing controls, labeling changes, additional testing requirements, restrictions of indicated uses or marketing, post-approval studies, post-marketing surveillance or product withdrawal or recall.

All of our drug products are manufactured, tested, packaged, stored, and distributed according to current Good Manufacturing Practice ("cGMP") regulations. The FDA performs periodic inspections and/or records audits to ensure that our facilities and quality systems remain in compliance with all appropriate regulations and agency expectations. Specific regulations and laws that impact our business include, but are not limited to:

•The FDCA gives authority to the FDA to oversee the safety of food, drugs, medical devices, cosmetics and other items. Following the 2012 enactment of the Food and Drug Administration Safety and Innovation Act, the FDCA incorporated, among other things, new user fee collection authority for prescription drugs. Since that time, user fee authority has been extended to OTC drugs, generic drugs and biosimilars and to additional supply chain parties.

•The FDCA is regularly modified by Congress in other ways, including modifying FDA’s authority regarding drug and device shortages and enhancing the FDA's inspection authority of the drug supply chain.

•The FDA Reauthorization Act of 2017 created a pathway by which the FDA may, at the request of an applicant, designate a drug with “inadequate generic competition” as a Competitive Generic Therapy.

•Public Health Service Act, as amended (PHS Act) The Public Health Service Act (PHSA) regulates biologics through Section 351, which outlines the requirements for the approval, licensing, and oversight of biological products.

Third parties develop and manufacture APIs for use in certain of our pharmaceutical products that are sold in the U.S. and other global markets. API manufacturers typically submit a drug master file to the FDA that provides proprietary information related to the API manufacturing process. The FDA inspects the manufacturing facilities to assess compliance and the facilities and procedures must be compliant before API may be imported into the U.S. Currently, API must also be associated to an active or approved FDA application in order to be imported into the U.S. unless it meets certain exemptions.

We are subject to the Medical Device Amendments of 1976 to the FDCA and its subsequent amendments in the U.S. The regulations issued thereunder provide for regulation by the FDA of the design, manufacture and marketing of medical devices, including some of our products marketed under our oral care and OTC businesses. All of our current medical devices fall under Class I or Class II of the regulations. These devices are also subject to other general controls established by the FDA, such as registration, listing, labeling, and reporting obligations.

The FDA’s new unified Human Foods Program is responsible for the regulation of food safety, including infant formula. The Nutrition Center of Excellence ensures the nutritional adequacy and safety of infant formula through the Office of Nutrition & Food Labeling, and the Office of Critical Foods conducts infant formula pre-market review.

Before marketing a particular infant formula, the manufacturer must provide regulatory agencies assurance of the nutritional quality of that particular formulation consistent with the FDA’s labeling, nutrient content, and manufacturer quality control requirements. A manufacturer must notify the FDA at least 90 days before the marketing of any infant formula that differs fundamentally in processing or in composition from any previous formulation produced by the manufacturer. We actively monitor this process and make the appropriate adjustments to remain in compliance with current FDA rules regarding cGMP, quality control procedures, quality factors, notification requirements, and reports and records for the production of infant formulas.

In addition, the FDCA requires infant formula manufacturers to test product composition and safety during production and shelf-life; to keep records on production, testing, and distribution of each batch of infant formula; to use cGMP and quality control procedures; and to maintain records of all complaints and adverse events, some of which may reveal the possible existence of a health hazard. The FDA conducts yearly inspections of all facilities that manufacture infant formula, inspects new facilities during early production runs, and collects and analyzes samples of infant formula.

The Organic Foods Production Act enacted under Title 21 of the 1990 Farm Bill established uniform national standards for the production and handling of foods labeled as "organic." Our infant formula manufacturing sites in Vermont, Ohio and Wisconsin adhere to the standards of the U.S. Department of Agriculture ("USDA") National Organic Program for production, handling, and processing to maintain the integrity of organic products and are certified and inspected by USDA-accredited certifiers, enabling them to produce and label organic products for U.S. and Canadian markets.

The U.S. Environmental Protection Agency ("EPA") is the main regulatory body in the United States governing environmental regulation. Laws administered by the EPA, often in partnership with state agencies, include but are not limited to the Clean Air Act; the Clean Water Act; the Resource Conservation and Recovery Act; the Comprehensive Environmental Response, Compensation and Liability Act; and the Federal Insecticide, Fungicide, and Rodenticide Act.

The U.S. Drug Enforcement Administration ("DEA") regulates certain drug products containing controlled substances and List I chemicals, such as pseudoephedrine, pursuant to the federal Controlled Substances Act ("CSA") and the Substance Use-Disorder Prevention that Promotes Opioid Recovery Treatment for Patients and Communities Act ("SUPPORT Act"). The CSA and DEA regulations impose registration, security, record keeping, suspicious order monitoring, reporting, storage, manufacturing, distribution, importation and other requirements upon legitimate handlers under the oversight of the DEA. The DEA categorizes controlled substances into Schedules I, II, III, IV, or V, with varying qualifications for listing in each schedule. We are subject to the requirements regarding List I chemicals. Our facilities that manufacture, distribute, import, or export any List 1 Chemicals must register annually with the DEA and are subject to inspection and enforcement action if determined to be out of compliance.

In the U.S., government healthcare programs such as Medicare and Medicaid, are important third-party payers for patients treated with our products. While these programs may cover OTC products under some circumstances, utilization of our products under these programs is limited. When covering our products, these programs regulate the amount pharmacies and other healthcare providers are paid for our products. We participate in multiple programs, and are subject to associated price reporting, payment, and other compliance obligations under each.

We are subject to various other federal, state, non-governmental, and local agency rules and regulations, including among others: U.S. federal anti-bribery laws; Federal Trade Commission regulation of advertising and marketing of consumer goods; consumer product safety requirements; state and federal privacy laws and regulations; laws requiring certain pharmaceutical manufacturers to track and report payments to physicians and teaching hospitals; and non-governmental standard-setting organizations such as the International Organization for Standardization ("ISO") and the United States Pharmacopoeia Convention, Inc. ("USP"). Compliance with the laws and regulations regarding the manufacture and sale of our current products and the discovery, development, and introduction of new products requires substantial effort, expense and capital investment.

We develop and manufacture products and market third-party manufactured products in regions outside the U.S., primarily Europe, Canada, and Australia, each of which has its own regulatory environment. Other regulatory agencies, organizations and legislation that may impact our business include, but are not limited to privacy regulations, transparency laws, anti-bribery laws, and rules and regulations on infant formula.

In the EU, as well as many other locations around the world, the manufacture and sale of medicinal products are regulated in a manner substantially similar to that of the U.S. requirements, which generally prohibit the handling, manufacture, marketing, and importation of any medicinal product unless it is properly registered in accordance with applicable law. However, obtaining regulatory approval across various EU member states can present complex challenges. The registration file relating to any particular product must contain data related to product efficacy and safety, including results of clinical testing and/or references to medical publications, as well as detailed information regarding production methods and quality control. Health ministries are authorized to cancel the registration of a product if it is found to be harmful or ineffective or if it is manufactured or marketed other than in accordance with registration conditions.

The EU has enacted into law numerous directives and adopted many harmonizing standards pertaining to a wide range of industrial products, including medical devices. Medical devices that comply with the requirements of applicable directives are entitled to bear the CE marking of conformity, which indicates that the device conforms to the applicable requirements of the directives and, accordingly, can be commercially distributed throughout Europe. The method of assessing conformity varies depending on the class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a Notified Body, an organization accredited by a member state under the EU's Medical Device Regulation ("MDR"). Assessment by a Notified Body includes an audit of the manufacturer’s quality system and may also include specific testing of the product. This assessment is a prerequisite for a manufacturer to commercially distribute the product throughout the EU. All medical devices will need to be approved under the MDR with transition periods until 2027-28, and the possibility to sell off existing medical device products until end of shelf-life.

Dietary supplements are subject to several regulations that inform the selection of ingredient levels and how products can be described on packaging and in advertising. These regulations include: Food Supplements Directive 2002/46/EC, Food Information to Consumers Regulation (EU) No 1169/2011, Permitted Vitamins and Minerals Regulation (EC) 1170/2009, Food Additives Regulation (EC) 1333/2008, Nutritional & Health Claims Regulation (EC) No 1924/2006, the Foods Intended for Particular Nutritional Uses Directive 2009/39/EC, Regulation (EU) 609/2013, and Regulation EC 1924/2006.

Cosmetic products in the EU market must comply with Regulation EC No. 1223/2009. This regulation requires manufacturers to prepare a product safety report prior to placing a cosmetic product in the market. In addition, for each cosmetic product placed in the market, a “responsible person” must be designated to oversee compliance with the regulation’s reporting requirements. Commission Regulation EU No. 655/2013 establishes the common criteria and justification for claims to be used in the packaging and advertising of cosmetics products.

Biocides in the EU market must comply with Regulation EU No. 528/2012 ("EU BPR") overseen by the European Chemicals Agency. Contrary to medicines, biocides are not exempted from chemical legislation such as the Regulation on Registration, Evaluation, Authorization and Restriction of Chemicals No. 1907/2006 and the Regulation on Classification, Labelling and Packaging Regulation of substances and mixtures EC No. 1272/2008.

The General Product Safety Directive (2001/95/EC) complements sector-specific legislation such as rules that apply to electrical and electronic goods, chemicals, and other specific product groups. Together, the General Product Safety Directive and sector specific legislation ensure the safety and traceability of products in the market (other than pharmaceuticals, medical devices, and food which are regulated under separate legislation). If our products fail to meet the General Product Safety Directive, we may incur fines.

We must comply with a variety of U.S. laws related to doing business outside of the U.S., including but not limited to, Office of Foreign Asset Controls; United Nations and EU sanctions; the Iran Threat Reduction and Syria Human Rights Act of 2012; rules relating to the use of certain “conflict minerals” under Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act; and regulations enforced by the U.S. Customs and Border Patrol. Changes in laws, regulations, and practices affecting the pharmaceutical industry and the healthcare system, including imports, exports, manufacturing, quality, cost, pricing, reimbursement, approval, inspection, and delivery of healthcare, may affect our business and operations. International sanctions and boycotts of our products could also impact our sales and ability to export our products.

Our principal executive offices are located at The Sharp Building, Hogan Place, Dublin 2, D02 TY74, and our North American base of operations is located at 430 Monroe Avenue NW, Grand Rapids, Michigan 49503. Our telephone number is +353 1 7094000. Our website address is www.perrigo.com, where we make available free of charge our reports on Forms 10-K, 10-Q and 8-K, including any amendments to these reports, as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission ("SEC"). These filings are also available to the public at www.sec.gov.

•We face competition from other consumer packaged goods and pharmaceutical companies, which may threaten the demand for and pricing of our products.

•If we do not continue to develop, manufacture, and market innovative products, introduce new line extensions, and expand into adjacent categories that meet customer demands, our net sales may be negatively impacted and we may lose market share.

•We operate in highly regulated industries, and any inability to timely meet current or future regulatory requirements could have a material adverse effect on our business and operating results.

•Limitations on reimbursement, continuing healthcare reforms, and changes to reimbursement methods in the United States and other countries may have an adverse effect on our financial condition and operating results.

•Unfavorable publicity or consumer perception of the safety, quality, and efficacy of our products could have a material adverse effect on our business.

•Lack of availability, or significant increases in the cost, of raw materials used in manufacturing our products could have a material adverse effect on our profit margins and operating results.

•The effects of public health outbreaks, including pandemics and epidemics, and related public and governmental actions could have a material adverse impact on our operations and our business and financial condition in the future.

•Disruption of our supply chain, including as a result of pandemics, global health crises, or wars or other civil unrest, including war in Ukraine, or in the Middle East, could have a material adverse effect on our businesses, financial condition, results of operations and cash flows.

•A disruption at any of our main manufacturing facilities could have a material adverse effect on our business, financial position, and results of operations.

•Our business could be negatively affected by the performance of our collaboration partners and suppliers, and any such adverse impact could be material.

•Our business depends upon certain customers for a significant portion of our sales, therefore our business would be adversely affected by a disruption of our relationship with these customers or any material adverse change in these customers' businesses.

•Our businesses could be adversely affected by deteriorating economic conditions in the countries in which we operate, and our results may be volatile due to these or other circumstances beyond our control.

•A cybersecurity breach, disruption or misuse of our information systems, or our external business partners’ information systems could have a material adverse effect on our business.

•Management transition creates uncertainties, and any difficulties we experience in managing such transitions may negatively impact our business.

•We may not realize the benefits of business acquisitions, divestitures, and other strategic transactions, which could have a material adverse effect on our operating results.

•We have acquired significant assets that could become impaired or subject us to losses and may result in an adverse impact on our results of operations, which could be material.

•There can be no assurance that our business strategy and related strategic initiatives, including restructurings, will be executed effectively or achieve their intended effects.

•The synergies and benefits expected from acquiring HRA Pharma and Gateway may not be realized in the amounts anticipated or at all and integrating HRA Pharma and Gateway's business may be more difficult, time consuming or costly than expected.

•Failure to effectively monitor and respond to ESG matters, including our ability to set and meet reasonable goals related to climate change and sustainability efforts, may negatively affect our business and operations.

•If we are unable to maintain effective internal control over financial reporting, investors could lose confidence in the accuracy and completeness of our financial reports and the market price of shares could be adversely affected.

•Our business, financial condition, and results of operations are subject to risks arising from the international scope of our operations.

•We operate in jurisdictions that could be affected by economic and geopolitical instability, which could have a material adverse effect on our business.

•The international scope of our business exposes us to risks associated with foreign exchange rates.

•We are or may become involved in lawsuits and may experience unfavorable outcomes of such proceedings.

•Increased scrutiny on pricing practices and competition, including antitrust enforcement activity by government agencies and class action litigation, may have an adverse impact on our business and operating results, which could be material.

•Third-party patents and other intellectual property rights may limit our ability to bring new products to market and may subject us to potential legal liability, which could have a material adverse effect on our business and operating results.

•The success of certain of our products depends on the effectiveness of measures we take to protect our intellectual property rights and patents.

•Our ability to achieve operating results in line with published guidance is inherently subject to numerous risks and other factors beyond our control. Publishing earnings guidance subjects us to risks, including increased stock volatility, that could lead to potential lawsuits by investors.

•Significant increases in the cost or decreases in the availability of the insurance we maintain could adversely impact our operating results and financial condition. Disputes with insurers on the scope of existing policies may limit the coverage available under such policies.

•The resolution of uncertain tax positions and ongoing disputes with U.S. and foreign tax authorities could be unfavorable, which could have a material adverse effect on our business.

•Changes to tax laws and regulations or the interpretation thereof could have a material adverse effect on our results of operations and the ability to utilize cash in a tax efficient manner.

•Our effective tax rate or cash tax payment requirements may change in the future, which could adversely impact our future results of operations.

•Our indebtedness could adversely affect our ability to invest in our business and implement our strategic initiatives.

•We cannot guarantee that we will buy back our ordinary shares pursuant to our announced share repurchase plan or that our share repurchase plan will enhance long-term shareholder value.

•Any additional shares we may issue could dilute your ownership in the Company.

•We are incorporated in Ireland; Irish law differs from the laws in effect in the United States and may afford less protection to, or otherwise adversely affect, our shareholders.

•We may be limited in our ability to pay dividends in the future.

Our Perrigo-branded products compete against store brand, generic, and branded health and wellness products. In addition, our products sold under labels of others (store brand) compete against other store brands, generic, and branded health and wellness products. If we or our store brand customers are unable to compete successfully, our business may lose customers or face negative pricing pressures. In particular:

•Our CSCA and CSCI segments experience direct competition from other companies, including brand name companies, that may try to prevent, discourage or delay the use of our products through various measures, including introduction of new products, legislative initiatives, changing dosage forms or dosing regimens, regulatory processes, filing new patents or patent extensions, lawsuits, citizens’ petitions, and attempts to generate negative publicity prior to our introduction of a new competitive product. Moreover, other companies may produce the same products as us, sometimes sold at dramatically lower margins in order to gain market share. Other companies may also introduce new products or delivery techniques that make our current products less desirable.

•Our competitors may be able to adapt more quickly to changes in customer requirements or develop products comparable or superior to those offered by us at more competitive prices.

•Competition in the markets in which we operate may also be impacted by changes in regulations and government pricing programs that may give certain competitors an advantage.

The growth of our business is due in large part to our ability to develop, manufacture, and market products that meet customer requirements for quality, safety, efficacy, and cost-effectiveness. Margins for existing products tend to decline over time due to aging product life cycles, changes in consumer preferences, pricing pressure from customers, and increased competition. Accordingly, our business model relies heavily on the continuous introduction of innovative products and new product categories. If we do not continue to develop, manufacture, and market new products, or if we fail to stay current with the latest manufacturing information, and packaging technology, we could lose market share, and our net sales may be negatively affected.

The development and commercialization process, particularly with respect to innovative products, is both time consuming and costly, and subject to a high degree of business risk. Products currently under development may require re-design to meet evolving regulatory standards, may not perform as expected, may not pass required bioequivalence studies, or may be the subject of intellectual property challenges. Necessary regulatory approvals may not be obtained in a timely manner, if at all. Even if we are successful in developing a product, our customers' failure to launch one of our products successfully, or delays in manufacturing developed products, could adversely affect our operating results. In addition, regulatory agencies may impose higher standards or additional requirements, as a condition to clearing new products, such as requiring more supporting data and clinical data than previously required, which could negatively impact our net sales. In our CSCA segment, we must prove that the regulated generic drug products are bioequivalent to their branded counterparts, which may require bioequivalence studies, and, in the case of topical products, even more extensive clinical endpoint trials to demonstrate their efficacy, and the failure to do so could also negatively impact our sales.

We operate in highly regulated industries, and any inability to timely meet current or future regulatory requirements could have a material adverse effect on our business and operating results.

We operate in highly regulated industries in numerous countries and are subject to the regulations of a variety of U.S. and non-U.S. agencies related to the manufacturing, processing, formulation, packaging, labeling, testing, storing, distribution, import, export, advertising, and sale (including cost, pricing and reimbursement) of our products, as described in detail in Item 1. Business - Government Regulation and Pricing. Changes in laws, regulations, and practices in the countries in which we operate, including changes in interpretation of existing regulations (which may have retroactive effect), may be difficult or expensive for us to comply with, could restrict or delay our ability to manufacture, distribute, sell or market our products, and may adversely affect our revenue, operating results, and financial condition or impose significant administrative burdens. Moreover, changes in the interpretation of existing regulations or practices by such regulators could result in changes in the legal requirements affecting us (including with retroactive effect). Divergence in regulatory approach from country to country, and between the EU and individual member states, adds cost and complexity to the compliance framework; and differences in requirements and/or implementation dates in different jurisdictions may provide competitive advantages to manufacturers that operate in other locations. If our products fail to meet regulatory requirements, our sales may be adversely affected, we may incur fines and penalties, and our exposure to liability relating to product-based claims may increase. Below are some examples of ways in which regulatory risk may impact us:

•On July 14, 2021, the European Commission adopted a set of proposals to ensure polices are aligned with the goal of reducing net greenhouse gas emissions by at least 55% by 2030 in comparison to 1990 (the "EU Green Deal"). As required under the Climate Law, the Commission also recommended, in February 2024, an additional intermediate target of 90% less emissions by 2040. There is a growing focus on environmental impact of self-care products, their ingredients, components, packaging, manufacturing, and disposal. This focus could lead to new requirements and restrictions in the coming years across all product categories.

•U.S. law encourages generic competition by providing eligibility for first generic marketing exclusivity if certain conditions are met. If we are granted generic exclusivity, the exclusivity may be shared with other companies; or we may forfeit 180-day exclusivity if we fail to obtain regulatory approval and begin marketing within the statutory requirements. If we are not the first to file our ANDA, the FDA may grant 180-day exclusivity to another company, thereby effectively delaying the launch of our product and/or possibly reducing our market share.

•U.S. and global regulatory agencies regularly inspect our manufacturing facilities and the facilities of our third-party suppliers for good manufacturing practices ("GMP") and other regulatory compliance. The failure of one of these facilities to comply with applicable laws and regulations may lead to a breach of representations made to our customers, or to regulatory or government action against us related to the products made in that facility, including suspension of or delay in regulatory approvals and product seizure, injunction, recall, suspension of production or distribution of our products, a total or partial shutdown of production in one or more facilities, loss of licenses or other governmental penalties, or civil or criminal prosecution, which could result in increased cost, lost revenue, or reputational damage.

•Regulatory agencies globally, including the FDA and the European Medicines Agency, have issued guidance on assessing and controlling nitrosamine impurities in medicine products. We are continuing to undertake a review of our product portfolio in accordance with regulatory guidance to assess the risk of the presence of nitrosamine impurities. Any finding of nitrosamine impurities exceeding levels set by regulatory authorities may require us to adopt modified product sourcing and/or manufacturing processes or to initiate product withdrawal.

•Rx-to-OTC switches are part of our future growth. If regulatory agencies fail to approve Rx-to-OTC switches in new product categories or reassess the terms of existing OTC classifications, our growth prospects and product mix would be impaired. Further, regulatory agencies may reassess the terms of OTC classification if they perceive a shift in the previously assessed benefit/risk profile. Any such reassessment could lead to OTC products reverting to prescription. For example, as described in Item 1. Business - Government Regulation and Pricing, Irish regulators are undertaking a formal review of non-prescription codeine products, which could result in the reclassification of codeine to prescription only after a brief transition period. A final opinion is expected in 2025. Sales of products containing codeine in Ireland were approximately $21 million in 2024. Moreover, a reclassification by Ireland could lead to reviews in other jurisdictions as well.

•Our infant formula products may be subject to barriers or sanctions imposed by countries or international organizations limiting international trade and dictating the content of such products. If governments enhance regulations on the infant formula industry through actions such as requiring additional testing or compulsory batch-by-batch inspection, or impose additional requirements on manufacturing practices, our sales and operating margins in this category could be adversely affected as it is costly to comply with such new regulations or requirements, and to develop compliant products and processes for our infant formula products. For example, in March 2023, the FDA released its "Immediate National Strategy to Increase the Resiliency of the U.S. Infant Formula Market" and issued a letter to the powdered infant formula industry to share information to assist the industry in improving the microbiologic safety of powdered infant formula and resiliency of the infant formula market. In response to the FDA's evolving regulatory expectations on infant formula and observations at our facilities, we shortened our production campaigns to perform more frequent major cleanings, implemented enhanced product testing and quality procedures, adopted new manufacturing protocols, and made additional infrastructure investments. As a result, we have been experiencing increased costs and lower production volumes and expect higher compliance costs moving forward.

•The regulation of List I chemicals complicate our supply chain, and adverse regulatory actions may result in temporary or permanent interruption of distribution of our products, withdrawal of our products from the market, or other penalties. If we are unable to obtain necessary quotas for List I chemicals, we risk having delayed product launches or failing to meet commercial supply obligations.

•In 2023, the European Parliament voted on a proposal to extend the EU's Medical Device Regulation ("MDR") transition periods until 2027-2028, together with an extended validity of existing medical device certificates and the possibility to sell off existing medical device products until end of shelf-life. With this decision the European Parliament took into account that there is currently a shortage in the number of Notified Bodies authorized to carry out conformity assessments required under MDR.

•Increased scrutiny of product classifications by government agencies can result in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including but not limited to, debarment from government business and prohibition to continue the business.

Increasing healthcare expenditures have received considerable public attention in many of the countries in which we operate. In the U.S., government programs such as Medicaid, as well as private insurers, have been focused on cost containment. In some markets in the EU and outside the U.S., the government provides healthcare at low direct cost to consumers and regulates pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system. Both private and governmental entities are seeking ways to reduce or contain healthcare costs through legislative and regulatory efforts, as further described in Item 1. Business - Government Regulation and Pricing, which could place further pricing pressure on our products and could negatively impact our operating results.

Under the Medicaid Drug Rebate Program ("MDRP"), a number of our products are considered non-innovator products and therefore subject to Medicaid federal upper limits ("FUL"), which restrict the amount state Medicaid programs reimburse for non-innovator covered outpatient drugs. While utilization of our products under the Medicaid program is limited, our products generally are subject to state Medicaid program payment methodologies, and may be subject to reimbursement pressures beyond our control.

We are dependent upon consumers' perception of the safety, quality, and efficacy of our products. Negative consumer perception may arise from media reports, social media posts, product liability claims, regulatory investigations, or recalls affecting our products or our industry, any of which may reduce demand or could damage our reputation and adversely affect our business.

•Our products involve risks such as product contamination, spoilage, mislabeling, and tampering that could require us to recall one or more of our products or could result in death or injury to consumers. Serious product quality concerns could also result in product liability lawsuits or governmental actions against us that, among other things, could result in additional costs, the suspension of production or distribution of our products, product seizures, loss of certain licenses, delays in the issuance of governmental approvals for new products, or other governmental penalties.

•We cannot guarantee that counterfeiting, imitation or other tampering with our products will not occur or that we will be able to detect and resolve it, which could lead to death or injury of consumers and negatively impact our reputation.

•Our nutritional product category is subject to certain consumer preferences and concerns, including the number of mothers who choose to use infant formula products rather than breastfeed their babies, which could change based on factors including increased promotion of the benefits of breastfeeding over the use of infant formula by private, public and government sources and changes in the number of families that are provided with infant formula by the U.S. federal government through the Women, Infants and Children program, which we do not participate in.

•With respect to our powdered infant formula products, a risk of contamination or deterioration may exist at each stage of the production cycle, including the purchase and delivery of raw materials, the processing and packaging of food products, and the use and handling by consumers, hospital personnel, and healthcare professionals. If certain of our infant formula products are found or alleged to have suffered contamination or deterioration, whether or not under our control, our reputation and our infant formula product category sales could be materially adversely affected. As described in Part II. Item 7, in response to the warning letter from the FDA in August 2023 and additional inspection observations at our Wisconsin infant formula facility, we have implemented new protocols and made additional infrastructure investments to address these observations. While all sites have returned to reliable, quality-assured production, we incurred certain extraordinary costs associated with the remediation and enhancement actions and expect higher ongoing operating costs at our infant formula manufacturing sites moving forward. Moreover, if we are unable to address the FDA's past or future observations to the FDA's satisfaction, we could incur additional compliance costs, and our reputation could be adversely affected if we are perceived by consumers to not be in compliance with such framework.

•Our financial success is dependent on positive brand recognition, which results in part from large investments in marketing over a period of years. The success of our brands may suffer if we do not continue to invest in marketing, or if our marketing plans or product initiatives are unsuccessful. In addition, an issue with one of our products could negatively affect the reputation of other products, potentially hurting our financial results.

•Negative social media posts or comments about us, store brands or generic pharmaceuticals, or our products could damage our reputation and adversely affect our business. Negative posts or comments about our products could result in increased pharmacovigilance reporting requirements, which may give rise to liability if we fail to fully comply with such requirements.

We rely on third parties to source many of our raw materials and to manufacture certain dosage forms that we distribute. Refer to Item 1. Business - Materials Sourcing. Certain raw materials may experience rapid cost increases due to increased labor, relevant commodities, energy costs and other inflationary pressures, and this may have a material negative impact on our financial results, whether or not we are able to pass on such increases to our customers. We maintain several single-source supplier relationships, either because alternative sources are not available or because the relationship is advantageous due to regulatory, performance, quality, support, or price considerations. Unavailability or delivery delays of single-source components or products could adversely affect our ability to ship the related product in a timely manner, a particularly severe effect for higher volume or more profitable products. It can take substantial time and investment to qualify an alternative supplier or material sources and establish reliable supply.

We maintain a strict program of verification and product testing throughout the ingredient sourcing and manufacturing process to identify potential counterfeit ingredients, adulterants, and toxic substances. Nevertheless, discovery of previously unknown problems with raw materials, product manufacturing processes, or new data suggesting an unacceptable safety risk, could result in a voluntary or mandatory withdrawal of the contaminated product from the marketplace, either temporarily or permanently. Any future recall or removal would result in additional costs and lost revenue, harm our reputation, and may give rise to product liability litigation.

Changes in regulation could impact the supply of the API and certain other raw materials used in our products. For example, the EU promulgated new standards requiring all API imported into the EU be certified as complying with Good Manufacturing Practices established by the EU. The regulations placed the certification requirement on the regulatory bodies of the exporting countries, which led to an API supply shortage in Europe as certain governments were not willing or able to comply with the regulation in a timely fashion, or at all. A shortage in API or other raw ingredients could cause us to have to cease manufacture of certain products, or to incur costs and delays to qualify other suppliers to substitute for those API manufacturers who are unable to export. This could have a material adverse effect on our business, results of operations, financial condition, and cash flow.

Moreover, our infant formula products require certain key raw ingredients that are derived from raw milk, which is influenced by factors beyond our control including seasonal and environmental factors, governmental agricultural and environmental policy, and global demand. Due to these factors, we cannot guarantee that there will be sufficient supplies of these key ingredients to produce infant formula.

As the COVID-19 pandemic demonstrated, the global economy and the self-care markets in which we compete are susceptible to impacts from public health crises.

Going forward, variants of COVID-19 or other public health incidents, including the actions taken to slow their spread, could have an adverse impact on our financial condition, our supply chains and other operations, our results of operations, consumer demand for our products and our ability to access capital. The magnitude of any such adverse impacts are not determinable, but could be material, depending on: the duration, intensity, and continued spread of the disease; the imposition of business or movement restrictions in various jurisdictions; the ability to develop vaccines and their availability, acceptance and efficacy; the severity and duration of any economic downturn resulting from such pandemic or other public health incidents; the effect of global supply chain and shipping challenges on the Company; the effectiveness of the Company's efforts at mitigation; and other factors, both known and unknown, many of which are likely to be outside our control.

Our ability to manufacture, deliver and sell our products is critical to our success. Damage or disruption to our collective supply or distribution capabilities resulting from pandemics and other health crises, including government responses thereto, labor shortages, armed hostilities, border closures, weather conditions, freight carrier availability, any potential effects of climate change, natural disasters, strikes or other labor unrest or other reasons could impair our ability to source inputs or ship, sell or timely deliver our products.

Competitors can be affected differently by any of these events depending on a number of factors, including the location of their suppliers and operations. Failure to take adequate steps to reduce the likelihood or mitigate the potential impact of any of these events, or to effectively manage such events if they occur, particularly when a commodity or raw material is sourced from or a product is manufactured at a single location, could adversely affect our business, financial condition, results of operations and cash flows and require additional resources to restore our supply chain.

As the war in Ukraine continues, supply chain disruptions in specific categories such as oil, agricultural and paper based commodities continue to lead to inflationary pressures in those areas. Any escalation of the conflict could lead to wider disruptions in our supply chain or have larger macroeconomic effects. Additionally, the conflict in the Middle East could impact our supply of API. Israel is a global technology research and development center that plays a critical role to the global API market, as a number of key suppliers are located within Israel. Perrigo sources some raw materials and finished goods from suppliers in Israel for certain self-care products, including Omeprazole. There is potential for some disruption as it relates to in-country logistics, including freight. As a precaution, Perrigo has engaged alternate suppliers to help minimize a potential supply disruption. Although there has not been any material impact on operations and we believe we have a strong mitigation plan in place, the conflict in the Middle East remains active and fluid and we could experience disruptions to our API supply. Future supply chain disruptions and inflationary pressures from the continuation of the conflicts between Russia and Ukraine, and escalating conflicts in the Middle East and neighboring regions, are uncertain.

Our manufacturing operations are concentrated in a few locations. Refer to Item 1. Business - Manufacturing and Distribution for more information. A significant disruption at one or more of these facilities, whether due to fire, natural disaster, power loss, intentional acts of vandalism, climate change, war, terrorism, insufficient quality, or pandemic could materially and adversely affect our business.

We have entered into strategic alliances with partners and suppliers to develop, manufacture, market and/or distribute certain products, or components of our products in various markets. We commit substantial effort, funds and other resources to these various collaborations. There is a risk that our investments in these collaborative arrangements will not generate the anticipated financial returns. While we believe our relationships with our partners and suppliers generally are successful, disputes, conflicting priorities or regulatory or legal intervention could be a source of delay or uncertainty as to the expected benefit of the collaboration. A failure or inability of our partners or suppliers to fulfill their collaboration obligations, or the occurrence of any of the risks above, could have an adverse effect on our business, financial condition, and results of operations.

We have one significant customer that represented 11.9% of our consolidated net sales for the year ended December 31, 2024. While we have other important customers, no other individual customer represents more than 10% of net sales. However, the loss of one or more of our customers could be material. We believe we have good relationships with all our customers. If our relationship with any of our significant customers, including the terms of doing business with the customers, changes significantly, or if one or more such customers were to experience difficulty in paying us on a timely basis, it could have a material adverse impact on us. The risk of such impacts would be increased by continued consolidation in the sector in which our customers operate. Refer to Item 1. Business - Significant Customers.

Additionally, if we are unable to maintain adequately high levels of customer service over time, customers may choose to assess penalties (where such penalties are contractually permitted), obtain alternate sources for products, and/or end their relationships with us.

Our customers could be adversely impacted if economic conditions worsen in the U.S. or other countries in which we operate. In the U.S., our consumer self-care business does not advertise our store brand products like national brand companies and thus, is largely dependent on retailer promotional activities to drive sales volume and increase market share. If our customers do not have the ability to invest in store brand promotional activities, our sales may suffer. Additionally, while we actively review the credit worthiness of our customers and suppliers, we cannot fully predict to what extent they may be negatively impacted by slowing economic growth. Our stock price may decline due to any earnings release or guidance that does not meet market expectations or other circumstances, which may be beyond our control, such as the severity, length and timing of the cough/cold/flu and allergy seasons, the timing of new product approvals and introductions by us and our competitors, and the timing of retailer promotional programs.

Our business operations are increasingly dependent upon information technology systems that are highly complex, interrelated with our external business partners, and may contain confidential information (including personal data, trade secrets or other intellectual property, or proprietary business information). The nature of digital systems, both internally and externally, makes them potentially vulnerable to disruption or damage from human error and/or security breaches, which include, but are not limited to, ransomware, data theft, denial of service attacks, sabotage, industrial espionage, interruptions or other system issues, unauthorized access and computer viruses. Such events may be difficult to detect, and once detected, their impact may be difficult to assess and address.

Cyber-attacks have become increasingly common. We have experienced immaterial business disruption, monetary loss and data loss as a result of phishing, business email compromise and other types of attacks. In addition, the rapid evolution and increased adoption of new technologies, such as artificial intelligence, may intensify our cybersecurity risks. While we continue to employ resources to monitor our systems and protect our infrastructure, these measures may prove insufficient, and that could subject us to significant risks, including, without limitation:

•Ransomware attacks, other cyber breaches or disruptions that impair our ability to develop products, meet regulatory approval requirements or deadlines, produce or ship products, take or fulfill orders, and/or collect or make payments on a timely basis;

•System issues, whether as a result of an intentional breach, a natural disaster or human error that damage our reputation and cause us to lose customers, experience lower sales volume, and/or incur significant liabilities;

•Significant expense to remediate the results of any attack or breach and to ensure compliance with any required disclosures mandated by the numerous global privacy and security laws and regulations; and

•Interruptions, security breaches, or loss, misappropriation, or unauthorized access, use or disclosure of confidential information,

which, individually or collectively, could result in financial, legal, business or reputational harm to us and could have a material adverse effect on our business, financial condition and results of operations.

We are also subject to numerous laws and regulations designed to protect personal data, such as the California Consumer Privacy Act in the U.S., the U.K.'s Data Protection Act of 2018 and the European General Data Protection Regulation ("GDPR"). These data protection laws introduced more stringent data protection requirements and significant potential fines, as well as increased our responsibility and potential liability in relation to personal data that we process and possess. Compliance with such laws require significant time and resources and may impose significant challenges that are likely to continue to increase over time, particularly as additional regulatory agencies adopt similar or new requirements. We have put mechanisms in place to ensure compliance with applicable data protection laws, but there can be no guarantee of their effectiveness. For more information regarding our cybersecurity activities, please refer to Item 1C. Cybersecurity.

We have experienced significant changes to our leadership team over the past several years. Patrick Lockwood-Taylor was appointed President, Chief Executive Officer and Board Member in 2023. In 2024, the Company appointed new leaders of its CSCA and CSCI segments with the appointments of Catherine "Triona" Schmelter as President Consumer Self-Care Americas and Roberto Khoury as President Consumer Self-Care International. We also appointed Charles Atkinson as our new General Counsel and Abbie Lennox as our Chief Science Officer and expanded our Chief Scientific Office, with Allison Ives tasked to head our new Disruptive Growth Team.

Additionally, David Ball was appointed as Chief Brand and Digital Officer. Although we believe these leadership transitions are in the best interest of our stakeholders, any change in executive management creates uncertainty. Moreover, changes in our Company as a result of management transition could have a disruptive impact on our ability to implement, or result in changes to, our strategy and could negatively impact our business, financial condition and results of operations.

In the normal course of business, we engage in discussions relating to possible acquisitions, divestitures, and other strategic transactions, some of which may be significant in size or impact. Transactions of this nature create substantial demands on management, operational resources, technology, and financial and internal control systems, and can be subject to government approvals or other closing conditions beyond the parties' control. In the case of acquisitions, we may face difficulties with integrating these businesses, managing expanded operations, achieving operating or financial synergies in expected timeframes or in new products or geographic markets. In the case of divestitures, including the disposition of the Rare Disease Business and the separation of the Rx business, we may face difficulty in effectively transferring contracts, obligations, facilities, and personnel to the purchaser, while minimizing continued exposure to risks and liabilities of the divested business. Moreover, the agreement for the sale of the Rare Diseases Business provided for up to €85 million in potential earnout payments based on the Rare Diseases Business achieving certain sales milestones. Should the business not perform up to these standards, we may not receive some or all of the earnout payments.

There are inherent uncertainties involved in identifying and assessing the value, strengths, and profit potential, as well as the weaknesses, risks, and contingent and other liabilities of acquisition targets, which can be affected by risks and uncertainties relating to government regulations and oversight as well as changes in business, industry, market or general economic conditions. For example, after our acquisition of Gateway, in response to the FDA's evolving regulatory expectations on infant formula and observations at our facilities, we have shortened our production campaigns to perform more frequent major cleanings and implemented enhanced product testing and quality procedures, resulting in additional costs and lower production volumes of infant formula than previously anticipated.

Moreover, the financing of any acquisition can have a material impact on our liquidity, credit ratings and financial position. Alternatively, issuing equity to pay all or a portion of acquisition purchase price would dilute our existing shareholders.    

Acquisitions and divestitures also involve costs, including fees and expenses of financial advisors, lawyers, accountants, and other professionals, and can involve retention bonuses and other additional compensation of employees or increase turnover in personnel. Any of these risks or expenses could have a negative effect on our financial condition or results of operations.

We have recorded significant goodwill and intangible assets on our balance sheet as a result of previous acquisitions, which could become impaired and lead to material charges in the future.

We perform an impairment analysis on intangible assets subject to amortization when there is an indication that the carrying amount of any individual asset may not be recoverable. Any significant change in market conditions, estimates or judgments used to determine expected future cash flows that indicates a reduction in carrying value may give rise to impairment in the period that the change becomes known. Goodwill, indefinite-lived intangible asset, and definite-lived intangible asset impairments are recorded in Impairment charges on the Consolidated Statements of Operations. As of December 31, 2024, the net book value of our goodwill and intangible assets were $3.3 billion and $2.4 billion, respectively. In the past three years, we have recognized a total of $178.9 million in asset impairments, across all segments and asset categories. Refer to Item 8. Note 9 for additional information related to our goodwill and intangible assets.

Our success is dependent in large part on our ability to implement our One Perrigo strategy and business model successfully. To drive our business model and improve financial performance, we are engaged in certain ongoing restructuring programs. In late 2022, we initiated our Supply Chain Reinvention Program, designed to increase operational efficiency and improve our return on invested capital by, among other goals, reducing portfolio complexity, investing in advanced planning capabilities, diversifying sourcing, and optimizing our manufacturing assets and distribution models. In addition, in 2024 we launched Project Energize, a global investment and efficiency program to drive the next evolution of the Company's capabilities and organizational agility. We also continue to invest in other initiatives, including innovation, information systems and tools, and our people to drive consistent and sustainable results. We believe these initiatives will reduce operating costs and/or enhance our net sales, operating margins, and earnings; however, certain of these initiatives require substantial costs during implementation, and there can be no assurance any of these initiatives will produce the anticipated benefits. Any increase in such costs or delay or failure to achieve the anticipated benefits could have a material adverse effect on our projected results.

Various factors may impact our ability to implement our strategies and realize their anticipated benefits. These factors include circumstances outside of our control such as increased competition, legal developments, government regulation, general economic conditions, increased operating costs or expenses and changes in industry trends or consumer preferences. In addition, implementing these changes will require a significant amount of management time and effort, which may disrupt our business or otherwise divert management’s attention from other aspects of our business, including our other strategic initiatives, possible organic or inorganic growth opportunities, and customer and vendor relationships. Any of the foregoing risks could materially adversely affect our business, results of operations, liquidity, and financial condition.

We may experience challenges integrating the Gateway business and managing our expanded operations, including the acquisition of HRA Pharma. Our ability to realize the benefits expected from the HRA Pharma and Gateway acquisitions will depend, in part, on our ability to successfully integrate the business, control costs and maintain growth. Integrations can be complex and time consuming, and the integration may result in temporarily depressed sales while integration of supply chain and distribution channels take place. Any delays, additional unexpected costs, or other difficulties encountered in the integration process could have a material adverse effect on the Company’s revenues, expenses, operating results and/or financial condition. While the integration of HRA Pharma was completed during 2023, activities related to the integration of Gateway continued into 2024.

Even if integration occurs successfully, we may not achieve projected synergies or level of anticipated sales growth in new products, brands, or geographic markets within the anticipated timeframe, or at all. There are inherent uncertainties involved in identifying and assessing the profit potential, value, strengths, weaknesses, risks, and contingent and other liabilities of acquisitions, such as HRA Pharma and Gateway, some of which can be affected by risks and uncertainties relating to government regulations and oversight as well as changes in the business, the industry, competition, consumer trends or general economic conditions. For instance, in response to the FDA's evolving regulatory expectations on infant formula, we have shortened our production campaigns to perform more frequent major cleanings and implemented enhanced product testing and quality procedures, resulting in additional costs and lower production volumes of infant formula.

Regulatory developments and stakeholder expectations relating to ESG matters are rapidly changing. Concern over climate and other environmental and social topics has increased focus on the sustainability of practices and products in the markets we serve, and compliance with new laws and regulations regarding these ESG topics may result in increased costs and disruption to operations. For example, The European Union’s Corporate Sustainability Reporting Directive (“CSRD”) significantly expands mandatory sustainability reporting in accordance with European Sustainability Reporting Standards (“ESRS”). While CSRD rules are prescriptive for the types of data to be reported, the standards to quantify and qualify such data are still evolving and uncertain. However, it is likely to impose significant increased costs on us related to complying with our reporting obligations and increase risks of noncompliance with ESRS and the CSRD. We are monitoring the rules and regulations related to CSRD and anticipate to be included in the CSRD’s scope beginning in 2025, with the initial reporting expected in 2026. In March 2024, the SEC released its final rule on climate-related disclosures, which would have required the disclosure of certain climate-related risks and financial impacts, as well as GHG emissions. Following a number of legal challenges, the implementation of these rules has been stayed pending review by the U.S. Court of Appeals for the Eight Circuit. In light of such pending litigation and the change in presidential administration, it is uncertain if and when such rules would take effect or in what form.

Moreover, the standards by which ESG matters are measured are rapidly evolving, and certain areas are subject to assumptions that could change over time. Stakeholder expectations are not uniform, and both opponents and proponents of various ESG-related matters have increasingly resulted in a range of activism and action to advocate for their positions. Navigating varying expectations of policymakers and other stakeholders has inherent costs, and any failure to successfully navigate such expectations may expose us to negative publicity, shareholder activism, and litigation of other engagement from stakeholders with opposing views, as well as the potential for civil investigations and enforcement by federal governmental authorities. If we are unable to recognize and respond to such developments, or if our existing practices and procedures are not adequate to meet new and changing regulatory requirements, market standards or investor expectations, some of which may be conflicting, we may miss corporate opportunities, become subject to regulatory scrutiny, litigation or third-party claims, or incur costs to revise operations to meet new or revised standards.

As a global organization, we have set goals to address the impact of our operations on climate change and related environmental and social issues. These targets include reducing carbon emissions and water usage as well as becoming fully reliant on renewable energy sources. Refer to Item 1. Business - Environmental. While challenging and aspirational, we believe these goals are obtainable, however, any failure or perceived failure to achieve our sustainability goals or to act responsibly with respect to such matters may negatively impact our operations and/or financial condition. While we monitor a broad range of ESG issues, there can be no assurance that we will manage such issues successfully, or that we will successfully meet the expectations of our stakeholders, consumers and employees.

As a publicly traded company, we are required to maintain effective internal controls over financial reporting and to report any material weaknesses in our internal control. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the accuracy and completeness of our financial reporting for external purposes in accordance with generally accepted accounting principles. We spend a substantial amount of management and other employee time and resources to comply with laws, regulations and standards relating to corporate governance and public disclosure. In particular, Section 404 of the Sarbanes-Oxley Act of 2002 requires management’s annual review and evaluation of our internal control over financial reporting and attestation as to the effectiveness of these controls by our independent registered public accounting firm. If we fail to maintain the adequacy of our internal controls, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting.

We manufacture, source raw materials, and sell our products in a number of countries. The percentage of our business outside the U.S. has been increasing. We are subject to risks associated with international manufacturing and sales, including changes in regulatory requirements. Refer to Item 1. Business - Government Regulations and Pricing, for changes to tax and import/export laws and trade and customs policies (including the enactment of tariffs on goods imported into the U.S., including but not limited to, goods imported from China), problems related to markets with different cultural norms or political systems, possible difficulties in enforcing agreements, longer payment cycles and shipping lead-times, difficulties obtaining export or import licenses, and imposition of withholding or other taxes. Moreover, the trade policies of the new U.S. presidential administration could result in substantial changes to tax or fiscal policies that could impact our business. For example, the administration has imposed, or indicated a willingness to impose, significant tariffs on products imported from a number of countries, which could impact our API procurement, products and manufacturing, or give rise to retaliatory tariffs on U.S. goods by those countries.

Additionally, we are subject to periodic reviews and audits by governmental authorities responsible for administering import and export regulations. To the extent that we are unable to successfully defend against an audit or review, we may be required to pay assessments, penalties, and increased duties.

Certain of our facilities operate in a special purpose sub-zone established by the U.S. Department of Commerce Foreign Trade Zone Board, which allows us certain tax advantages on products and raw materials shipped through these facilities. If the Foreign Trade Zone Board were to revoke the sub-zone designation or limit our use, we could be subject to increased duties.

Although we believe that we conduct our business in compliance with applicable anti-corruption, anti-bribery and economic sanctions laws, if we are found to not be in compliance with such laws or other anti-corruption laws, we could be subject to governmental investigations, legal or regulatory proceedings, substantial fines, and/or other legal or equitable penalties. This risk increases in locations outside of the U.S., particularly in locations that have not previously had to comply with the FCPA, U.K. Bribery Act 2010, Irish Criminal Justice (Corruption Offenses) Act 2018, and similar laws.

Our operations and supply partners could be affected by economic or political instability, embargoes, military hostilities, unstable governments and legal systems, inter-governmental disputes, travel restrictions, terrorist acts, and other armed conflicts. The global nature of our business involves the following risks, among others:

•The U.S. Department of State and other governments have at times issued advisories regarding travel to certain countries in which we do business, causing regulatory agencies to curtail or prohibit their inspectors from traveling to inspect facilities. If these inspectors are unable to inspect our facilities, the regulatory agencies could withhold approval for new products intended to be produced at those facilities.

•As a result of the exit of the U.K. from the E.U. (“Brexit”), which occurred in 2020, we continue to experience uncertainty surrounding certain of our businesses. While the E.U. and U.K. ratified a Trade and Cooperation Agreement (the “TCA”) that sets forth a framework for cooperation between the E.U. and U.K., including the mutual recognition of GMP inspections of manufacturing facilities for medicinal products, it does not contain wholesale mutual recognition of pharmaceutical regulations and product standards, and the E.U. and the U.K. continue to amend legislation and regulations post-Brexit. We continue to monitor for divergence between E.U. and U.K. regulations that could negatively impact our supply chain operations or other product development or sales operations.

Moreover, financial volatility and geopolitical instability outside the U.S. may impact our operations or affect global markets. As noted above, the war in Ukraine and the conflict in the Middle East continue to impact our operations and supply chain and any escalation of these conflicts could have a larger impact that expands into other markets where we do business, including our supply chain, business partners and customers in the broader region, which could result in lost sales, supply shortages, increase manufacturing costs and lost efficiencies. Further, the conflict may adversely impact macroeconomic conditions and increase volatility in and affect our ability to access capital markets and external financing sources on acceptable terms or at all. Given the international scope of our operations, such effects of ongoing wars and armed conflicts, and others we cannot anticipate, could adversely affect our business, business opportunities, operations, and financial results.

We report our financial results in U.S. dollars. However, a significant portion of our revenues, expenses, assets, indebtedness and other liabilities are denominated in foreign currencies. These currencies include, among others, the Euro, British pound, Canadian dollar, Swedish Krona, Chinese Yuan, Danish Krone, and Polish Zloty. Fluctuations in currency exchange rates, including as a result of inflation, central bank monetary policies, currency controls or other currency exchange restrictions have had, and could continue to have, an adverse impact on our financial performance. We may seek to mitigate the risk of such impacts through hedging, but such hedging activities may be costly and may not be effective.

In addition, emerging market economies in which we operate may be particularly vulnerable to the impact of rising interest rates, inflationary pressures, weaker oil and other commodity prices, and large external deficits. Risks in one country can limit our opportunities for portfolio growth and negatively affect our operations in another country or countries. Such conditions or developments could have an adverse impact on our operations. In addition, we may be exposed to credit risks in some of those markets.

We may become involved in lawsuits arising from a wide variety of commercial, manufacturing, development, marketing, sales and other business-related matters, including, but not limited to, competitive issues, pricing, contract issues, intellectual property matters, false advertising, antitrust or unfair competition, taxation matters, workers' compensation, product quality/recall, environmental remediation, securities law, disclosure, product liability and regulatory issues. Litigation is unpredictable and could result in potentially significant monetary damages, and we could incur substantial legal expenses, even if a claim against us is unsuccessful. We intend to vigorously defend against any lawsuits, however, we cannot predict how the cases will be resolved. Adverse results in, or settlements of, such cases could result in substantial monetary judgments. No assurance can be made that litigation will not have a material adverse effect on our reputation, financial position or results of operations in the future. Refer to Item 8. Note 19.

The actual or alleged presence of certain hazardous substances or petroleum products on, under or in our currently or formerly owned property, or from a third-party disposal facility that we may have used, or the failure to remediate them, could have adverse effects, including, for example, substantial investigative or remedial obligations and limitations on our ability to sell or rent affected property or to borrow funds using affected property as collateral. There can be no assurance that environmental liabilities and costs will not have a material adverse effect on us. Refer to Item 1. Business - Environmental for more information related to environmental remediation matters.

There has been increased scrutiny regarding sales, marketing, and pricing practices, including criminal antitrust investigations regarding drug pricing, civil False Claims Act investigations relating to drug pricing and marketing, multiple civil antitrust litigation initiated by governmental and private plaintiffs against pharmaceutical manufacturers and individuals, and related media reports.

Perrigo has been named as a co-defendant with certain other generic manufacturers in a number of class action, individual plaintiff direct action, State Attorney General, and county lawsuits alleging that we engaged in anti-competitive behavior to fix or raise the prices of certain drugs starting, in some instances, as early as calendar year 2010. Refer to Item 8. Note 19. While we intend to defend these lawsuits vigorously, any adverse decision could have a material adverse impact on our business, results of operations and reputation.

In addition, in May 2018, Perrigo was also served with and responded to a civil investigative demand in connection with a related civil False Claims Act investigation by the Civil Division of the Department of Justice. Although no charges or other related civil claims have been brought to date against Perrigo or any of our current employees (or, to the best of our knowledge, former employees), by the Department of Justice, we take the investigation very seriously.

The manufacture, use and sale of new products that are the subject of conflicting patent rights have been the subject of substantial litigation in the self-care and pharmaceutical industries.

•As a manufacturer of generic products, the ability of our CSCA and CSCI segments to bring new products to market is often limited by third-party patents or proprietary rights and regulatory exclusivity periods awarded on products. Launching new products prior to resolution of intellectual property issues may result in us incurring legal liability if the related litigation is later resolved against us. The cost and time for us to develop Rx-to-OTC switch products is significantly greater than the rest of the new products that we introduce. Any failure to bring new products to market in a timely manner could cause us to lose market share, and our operating results could suffer.

•We may have to defend against charges that we infringed patents or violated proprietary rights of third parties. This could require us to incur substantial expense and could divert significant effort of our technical and management personnel. If we are found to have infringed rights of others, we could lose our right to develop or manufacture some products or could be required to pay monetary damages or royalties to license proprietary rights from third parties. Additionally, if we choose to settle a dispute through licensing or similar arrangements, the costs associated with these arrangements may be substantial and could include ongoing royalties. An adverse determination in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling a number of our products.

•At times, our CSCA segment may seek approval to market drug products before the expiration of a third party's patents for therapeutically equivalent products, based upon our belief that such patents are invalid, unenforceable or would not be infringed by our products. In these cases, we may face significant patent litigation. Depending upon a complex analysis of a variety of legal and commercial factors, we may, in certain circumstances, elect to market a store brand or generic product while litigation is pending, before any court decision, or while an appeal of a lower court decision is pending, known as an "at risk" launch. The risk involved in an "at risk" launch can be substantial because, if a patent holder ultimately prevails, the remedies available to the patent holder may include, among other things, damages measured by the profits lost by the holder, which are often significantly higher than the profits we make from selling the generic version of the product. By electing to proceed in this manner, we could face substantial damages if we receive an adverse final court decision. In the case where a patent holder is able to prove that our infringement was "willful" or "exceptional," under applicable law, the patent holder may be awarded up to three times the amount of its actual damages or we may be required to pay attorneys’ fees.

    

If we fail to adequately protect our intellectual property, competitors may manufacture and market similar products.

•We have been issued patents covering certain of our products, and we have filed, and expect to continue to file, patent applications seeking to protect newly developed technologies and products in various countries. Any existing or future patents issued to or licensed by us may not provide us with any significant competitive advantages for our products or may even be challenged, invalidated, or circumvented by competitors. In addition, patent rights may not prevent our competitors from developing, using, or commercializing non-infringing products that are similar or functionally equivalent to our products.

•We also rely on trade secrets, unpatented proprietary know-how, and continuing technological innovation that we seek to protect, in part by confidentiality agreements with licensees, suppliers, employees, and consultants. If these agreements are breached, we may not have adequate remedies for any such breach. Disputes may arise concerning the ownership of intellectual property or the applicability of confidentiality agreements. Furthermore, trade secrets and proprietary technology may otherwise become known or be independently developed by competitors or, if patents are not issued with respect to products arising from research, we may not be able to maintain the value of such intellectual property rights.

Because we publish earnings guidance, we are subject to several risks. Earnings guidance is inherently uncertain and subject to factors beyond our control. Actual results may vary from the guidance we provide investors from time to time, such that our stock price may decline following, among other things, any earnings release or guidance that does not meet market expectations. 

It has become increasingly commonplace for investors to file lawsuits against companies following a rapid decrease in market capitalization. We have been in the past, are currently, and may be in the future, named in these types of lawsuits. These types of lawsuits can be costly and divert management attention and other resources away from our business, regardless of their merits, and could result in adverse settlements or judgments. The inherent uncertainty of earnings guidance and related lawsuits could have a material impact on us.

To protect against various potential liabilities, we maintain a variety of insurance programs, including property, general, product, and directors' and officers' liability. We may reevaluate and change the types and levels of insurance coverage that we purchase. Insurance costs, including deductible or retention amounts, may increase, or our coverage could be reduced, which could lead to an adverse effect on our financial results depending on the nature of a loss and the level of insurance coverage we maintained. Moreover, we are self-insured when insurance is not available, not offered at economically reasonable premiums or does not adequately cover claims brought against us. Our business inherently exposes us to claims, and an unanticipated payment of a large claim may have a material adverse effect on our business.

We may also disagree with our insurers on the scope of coverage provided. For example, in May 2021, insurers on multiple policies of D&O insurance filed an action in the High Court in Dublin against us and our current and former directors and officers seeking declaratory judgments on certain coverage issues. While we were successful in the High Court action, and ultimately reached a settlement of this matter while it was on appeal, as noted in Item 8. Note 19, future disputes with insurers regarding the scope of coverage under the existing or future policies may result in reductions in coverage or increased costs.

Although we believe our tax estimates are reasonable and our tax filings are prepared in accordance with applicable tax laws, the final determination with respect to any tax audit or any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results or cash flows in the periods for which that determination is made and in future periods after the determination. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties or interest assessments. See Item 8. Note 18 for a description of current audits and adjustment-related disputes and related litigation.

Although we are incorporated in Ireland, the IRS may assert that we should be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal tax purposes pursuant to section 7874 of the U.S. Internal Revenue Code of 1986, as amended ("Code"). For U.S. federal tax purposes, a corporation generally is considered a tax resident in the jurisdiction of its organization or incorporation. Because we are an Irish incorporated entity, we would generally be classified as a foreign corporation (and, therefore, a non-U.S. tax resident) under these rules. Section 7874 of the Code provides an exception under which a foreign incorporated entity may, in certain circumstances, be treated as a U.S. corporation for U.S. federal tax purposes. Refer to Item 1. Business - Government Regulation and Pricing.

We believe that under current law, we should be treated as a foreign corporation for U.S. federal tax purposes. However, there is limited guidance regarding the section 7874 provisions.

An unfavorable determination on Perrigo Company plc’s treatment as a foreign corporation under section 7874 of the Code or changes to the inversion rules in section 7874 of the Code, the IRS Treasury regulations promulgated thereunder, or other IRS guidance and legislative proposals aimed at expanding the scope of U.S. corporate tax residence could adversely affect our status as a foreign corporation for U.S. federal tax purposes, which could have a material impact on our Consolidated Financial Statements in future periods.

Additionally, we are subject to tax laws in various jurisdictions globally. Refer to Item 1. Business - Government Regulation and Pricing for a discussion of recent changes to U.S. and EU tax laws. Any of these changes could have a prospective or retroactive application to us, our shareholders, and affiliates, and could adversely affect us by changing our effective tax rate and limiting our ability to utilize cash in a tax efficient manner.

A number of factors may adversely impact our future effective tax rate or cash tax payment requirements, which may impact our future results and cash flows from operations. Refer to Item 8. Note 18. These factors include, but are not limited to: changes to income tax rates, to tax laws or the interpretation of such tax laws (including additional proposals for fundamental international tax reform globally); the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; adjustments to our interpretation of transfer pricing standards, treatment or characterization of intercompany transactions, changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in U.S. generally accepted accounting principles; expiration or the inability to renew tax rulings or tax holiday incentives; and divestitures of current operations.

Our business requires continuous capital investments, and there can be no assurance that financial capital will always be available on favorable terms or at all. Additionally, our leverage and debt service obligations could adversely affect the business. At December 31, 2024, our total indebtedness outstanding was $3.6 billion.

The agreements governing our Senior Secured Credit Facilities (as defined in Item 8. Note 12) impose material operating and financial restrictions that limit our operating flexibility, including the following:

•The Credit Agreement (as defined below) governing our Senior Secured Credit Facilities contain, and agreements governing our other indebtedness may contain, a number of restrictions and covenants that, among other things, limit our ability and/or our restricted subsidiaries’ ability to:

•incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons;

•pay dividends or distributions or redeem or repurchase capital stock;

•prepay, redeem or repurchase certain debt;

•make loans, investments, acquisitions (including certain acquisitions of exclusive licenses) and capital expenditures;

•enter into agreements that restrict distributions from our subsidiaries;

•enter into transactions with affiliates;

•enter into sale and lease-back transactions;

•sell, transfer or exclusively license certain assets, including material intellectual property, and capital stock of our subsidiaries; and

•consolidate or merge with or into, or sell substantially all of our assets to, another person.

•The Credit Agreement governing our Senior Secured Credit Facilities contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum first lien secured leverage ratio.

•As a result of these restrictions, we may be limited in how we conduct our business; unable to raise additional debt or equity financing to operate during general economic or business downturns; or unable to compete effectively, take advantage of new business opportunities or grow in accordance with our plans.

•Our failure to comply with any of the covenants could result in a default under the Credit Agreement and certain other indebtedness, which, if not cured or waived, could result in us having to repay our borrowings before their due dates. Such default may allow the lenders or other note holders to accelerate the related debt and may result in the acceleration of any other debt to which cross-acceleration or cross-default provision applies. If we are forced to refinance these borrowings on less favorable terms or if we were to experience difficulty in refinancing the debt prior to maturity, our results of operations or financial condition could be materially affected. In addition, an event of default under the Credit Agreement may permit the lenders to refuse to permit additional borrowings under the Revolver (as defined below) or to terminate all commitments to extend further credit under the Revolver. Furthermore, if we are unable to repay the amounts due and payable under the Credit Agreement or other debt instruments, the lenders and note holders may be able to proceed against the collateral granted to them to secure that indebtedness. If our indebtedness is accelerated, there can be no assurance that we would be able to repay or refinance our debt or obtain sufficient new financing.

•Future downgrades to our credit ratings may limit our access to capital and materially increase borrowing costs on current or future financing, including via trade payables with vendors. Customers' inclination to purchase goods from us may also be affected by the publicity associated with deterioration of our credit ratings.

•There are various maturity dates associated with our Senior Secured Credit Facilities, senior notes, and other debt facilities. There is no assurance that cash, future borrowings or equity financing will be available for the payment or refinancing of our indebtedness. Further, there is no assurance that any future refinancing or renegotiation of our Senior Secured Credit Facilities, senior notes or other debt facilities, or additional agreements will not have materially different or more stringent terms. Refer to Item 7. Management’s Discussion and Analysis - Capital Resources.

In October 2018, our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program. During the years ended December 31, 2024 and December 31, 2023, we did not repurchase any shares under such authorization, and there can be no assurances that we will do so in the future. The specific timing and amount of additional buybacks under the authorization, if any, will depend upon several factors, including market and business conditions, the trading price of our ordinary shares, the nature of other investment opportunities, the availability of our distributable reserves and the tax consequences of any buybacks. In addition, our ability to repurchase shares may be limited in the future under Irish law, if at any time we do not have sufficient distributable reserves. No share repurchases are currently anticipated in the near term.

Buybacks of our ordinary shares could affect the market price of our ordinary shares, increase their volatility or diminish our cash reserves, which may impact our ability to finance future growth and to pursue possible future strategic opportunities and acquisitions. Although our share repurchase plan is intended to enhance long-term shareholder value, there is no assurance that it will do so, and short-term share price fluctuations could reduce the plan’s effectiveness.

Under Irish law, our authorized share capital can be increased by an ordinary resolution of our shareholders, and the directors may issue new ordinary or preferred shares up to a maximum amount equal to the authorized but unissued share capital, without shareholder approval, once authorized to do so by the articles of association or by an ordinary resolution of our shareholders.

Subject to specified exceptions, Irish law grants statutory preemption rights to existing shareholders to subscribe for new issuances of shares for cash, but allows shareholders to authorize the waiver of the statutory preemption rights either in our articles of association or by way of a special resolution. Such disapplication of these preemption rights can either be generally applicable or be in respect of a particular allotment of shares.

        

As an Irish company, we are governed by the Irish Companies Act 2014 (the "Act"). The Act differs in some material respects from laws generally applicable to U.S. corporations and shareholders, including the provisions relating to interested directors, mergers, amalgamations and acquisitions, takeovers, shareholder lawsuits, and indemnification of directors.

•Under Irish law, the duties of directors and officers of a company are generally owed to the company only. As a result, shareholders of Irish companies do not have the right to bring an action against the directors or officers of a company for the breach of such duties, except in limited circumstances.

•Shareholders may be subject to different or additional tax consequences under Irish law as a result of the acquisition, ownership and/or disposition of ordinary shares, including, but not limited to, Irish stamp duty, dividend withholding tax, Irish income tax, and capital acquisitions tax.

•There is no treaty between Ireland and the U.S. providing for the reciprocal enforcement of foreign judgments. Before a foreign judgment would be deemed enforceable in Ireland, the judgment must be (i) for a definite sum, (ii) provided by a court of competent jurisdiction and (iii) final and conclusive. An Irish High Court may exercise its right to refuse to recognize and enforce a foreign judgment if the foreign judgment was obtained by fraud, if it violated Irish public policy, if it is in breach of natural justice, or if it is irreconcilable with an earlier judgment.

•An Irish High Court may stay proceedings if concurrent proceedings are being brought elsewhere. Judgments of U.S. courts of liabilities predicated upon U.S. federal securities laws may not be enforced by Irish High Courts if deemed to be contrary to public policy in Ireland.

•It could be more difficult for us to obtain shareholder approval for a merger or negotiated transaction than if we were a U.S. company because the shareholder approval requirements for certain types of transactions differ, and in some cases are greater, under Irish law.

•Additionally, under the Irish Takeover Panel Act issued in 1997 and Takeover Rules issued in 2022, the Board of Directors is not permitted to take any action that might frustrate an offer for our ordinary shares, including issuing additional ordinary shares or convertible equity, making material acquisitions or dispositions, or entering into contracts outside the ordinary course of business, once the Board of Directors has received an approach that may lead to an offer or has reason to believe that such an offer is or may be imminent, subject to certain exceptions. These provisions may give the Board of Directors less ability to control negotiations with hostile offerors and protect the interests of holders of ordinary shares than would be the case for a corporation incorporated in a jurisdiction of the United States.

A number of factors may limit our ability to pay dividends, including, among other things:

•Our ability to receive cash dividends and distributions from our subsidiaries;

•Compliance with applicable laws and debt covenants;

•Our financial condition, results of operations, capital requirements, general business conditions, and other factors that our Board of Directors may deem relevant; and

•The availability of our distributable reserves.

Under Irish law, distributable reserves are the accumulated realized profits so far as not previously utilized by distribution or capitalization, less accumulated realized losses so far as not previously written off in a reduction or a reorganization of capital duly made, subject to adjustments for any increases to, or reductions of, share premium. In addition, no distribution or dividend may be made if, at the time of the distribution or dividend, our net assets are not, or would not be, after giving effect to such distribution or dividend, be equal to, or in excess of, the aggregate of our called-up share capital plus undistributable reserves.

While we currently expect to continue paying dividends, significant changes in our business or financial condition such as asset impairments, sustained operating losses and the selling of assets, could impact the amount of distributable reserves available to us. On July 18, 2023, the Irish High Court approved the creation of $4,900 million of distributable reserves of the Company through the reduction of the Share Premium account. The court order authorizing the creation of distributable reserves was filed with the Registrar of Companies in Ireland and became effective on July 20, 2023.

Additionally, we are subject to financial covenants in our Senior Secured Credit Facilities. Our failure to comply with these covenants could trigger events, which could result in the acceleration of the related debt. Refer to Item 7. Management's Discussion and Analysis - Capital Resources for more information.

Cybersecurity is an important part of our risk management program and an area of increasing focus for our Board of Directors and management. We use a risk-based approach to identify, assess, protect, detect, respond to and recover from cybersecurity threats. While management is responsible for the day to day risk management, the Board of Directors, is responsible for the Company's overall risk oversight function, including cybersecurity risks. The Nominating & Governance Committee ("NGC") supports the Board of Directors by overseeing cybersecurity risks, policies and objectives. The Audit Committee supports the Board of Directors in overseeing the framework for risk assessments and enterprise risk management ("ERM") process. The Company’s cybersecurity policies, standards and processes are designed and implemented in light of the requirements of the National Institute of Standards and Technology ("NIST") frameworks for cybersecurity and privacy.

Recognizing that no single technology, process or business control can effectively prevent or mitigate all risks, we employ multiple technologies, processes and controls, all working as part of a cohesive strategy to minimize risk including the following:

•We emphasize security and resiliency through business assurance capabilities and incident response plans designed to identify, evaluate, and remediate incidents when they occur. We regularly review and update our plans, policies and technologies and conduct regular training exercises and crisis management preparedness activities to test their effectiveness.

•Perrigo leverages the NIST cybersecurity framework to measure the capability of its cybersecurity program and we conduct third party assessments to measure the NIST ratings.

•We maintain a cybersecurity risk register which is reviewed periodically with relevant stakeholders. Risks that are higher in impact are included within our Enterprise Risk Register which is reviewed with Executive Leadership and the Board of Directors.

•Our processes used to identify, assess, protect, detect, respond to and recover from cybersecurity threats is regularly tested by external parties through penetration testing, and other exercises designed to assess and test our cybersecurity health, resiliency and the effectiveness of our program.

•Management invests in organization capability and technology to manage and identify cybersecurity and information security risks. Our Company has information security employees across the globe, enabling us to monitor and promptly respond to threats and incidents, identify and maintain oversight of cybersecurity risks associated with third parties, evaluate and deploy cybersecurity technologies, and educate associates on cybersecurity risks.

•We maintain cyber insurance coverage to help mitigate possible costs associated with a potential incident.

•We have implemented an information and cybersecurity awareness program designed to educate and test employee maturity at least annually, and regularly throughout the year employees receive training regarding phishing and other threat actor schemes, the inherent risks involved in human interaction with information and operational technology, and new and emerging technologies.

We have processes in place designed to allow us to oversee and identify risks from cybersecurity threats associated with our use of third party service providers and suppliers through our Supplier Cyber Risk Assessment process, which assesses third-party cybersecurity controls through a combination of risk assessment questionnaires, commercially available risk data and security rating platforms. We also include cybersecurity and information security language in our contracts where applicable. We require our suppliers and partners to report cybersecurity incidents to us so that we can assess the impact of such an incident on us and have dedicated processes to respond to cybersecurity incidents at third parties. We have established processes to contain the impact of potential security incidents on Perrigo's third party service providers.

As of December 31, 2024, we are unaware of any risks from cybersecurity threats (including previous cybersecurity incidents) that may have materially affected or are reasonably likely to materially affect the Company's business strategy, results of operations or financial condition. We have experienced and may continue to experience cybersecurity incidents; however, we do not believe any cybersecurity incidents incurred to date have materially affected our Company, including our business strategy, results of operations, or financial condition. While we continue to employ resources to monitor our systems and protect our infrastructure, these measures may prove insufficient, and that could subject us to significant risks. For further discussion of how these and other potential cybersecurity risks may impact our business, refer to the risk factor under heading “A cybersecurity breach, disruption or misuse of our information systems, or our external business partners’ information systems could have a material adverse effect on our business” in Item 1A. Risk Factors – Operational Risks.

Our overall information security efforts are led by the Chief Information Security Officer ("CISO"). The CISO has substantial experience in cybersecurity, including knowledge, skills, certifications, and background in the field. The CISO holds several key certifications including Certified Information Systems Security Professional ("CISSP"), Certified Secure Software Lifecycle Professional ("CSSLP") and Certified Ethical Hacker ("CeH").

While management is responsible for day-to-day risk management, the Board of Directors is responsible for the Company’s overall risk oversight function, including cybersecurity risks, and includes oversight by several committees. The NGC, comprised solely of independent directors, supports the Board of Directors by overseeing cybersecurity risks, policies and objectives. As a part of its duties, the NGC regularly provides reports to the full Board of Directors.

The NGC routinely engages with the Chief Financial Officer (“CFO”), the CISO and Senior Vice President on a range of cybersecurity-related topics, including threats to the environment and vulnerability assessments, policies and practices, technology trends and regulatory developments. The NGC conducts regular committee meetings prior to each regular Board of Directors meeting and convenes additional sessions as necessary to address a specific cybersecurity threat.

Perrigo has an incident response team comprised of the CISO and senior leadership from Legal, Human Resources and Finance. We have a formalized breach management protocol and playbooks that are tested periodically. Perrigo uses a panel of forensic and third party service providers to assist the Company with its response in the event of a cybersecurity incident. We employ escalation procedures designed to notify management of certain specific cybersecurity threats or incidents. If deemed appropriate, management will notify the NGC, which may convene to discuss the cybersecurity threat before reporting to the Board of Directors on the matter.

Our world headquarters is located in Dublin, Ireland, and our North American base of operations is located in Grand Rapids, Michigan. We manufacture products at 16 worldwide locations and have R&D, logistics, and office support facilities in many of the regions in which we operate. We own approximately 80% of our facilities and lease the remainder. Our primary facilities by geographic area were as follows at December 31, 2024:

We believe that our production facilities are adequate to support the business, and our property and equipment are well maintained. Our manufacturing plants are suitable for their intended purposes and have capacities for current and near term projected needs of our existing products.

Information regarding our current legal proceedings is presented in Item 8. Note 19.

Our executive officers and their ages and positions as of February 21, 2025 were:

Title and Business Experience

Age

Charles Atkinson

Charles Atkinson was named Executive Vice President, General Counsel & Secretary, in October 2024. Mr. Atkinson joins Perrigo from Haleon plc and its predecessor, GSK plc, most recently serving as chief legal and compliance officer and Interim General Counsel. During his 20-plus year combined tenure at Haleon/GSK, Mr. Atkinson successfully advised across numerous transactions and integrations, including the creation of Haleon and subsequent separation from its parent shareholders GSK and Pfizer. He has also served as global head of corporate legal and was lead counsel for various parts of the self-care business, including supply chain, R&D and innovation, business development, and intellectual property.

48

David Ball

Dr. Ball was named Executive Vice President and Chief Brand and Digital Officer in August 2024. Prior to joining Perrigo, Dr. Ball was most recently at Bayer Consumer Healthcare and Care/of (prior to its acquisition by Bayer in 2020) from 2019 to 2024, where he held various positions including General Manager and Vice President of Marketing for the Digestive Health business in North America. Prior to this, Dr. Ball spent more than eight years at Procter and Gamble in leadership positions across multiple business units and functions.

45

Eduardo Bezerra

Eduardo Bezerra joined Perrigo in May 2022 as Executive Vice President and Chief Financial Officer. Mr. Bezerra previously served as Senior Vice President and Chief Financial Officer for Del Monte Fresh Produce, Inc., from 2019 to 2022. Before that, Mr. Bezerra held a number of positions of increasing responsibility at Monsanto Company from 1998 to 2018.

50

Ronald C. Janish

Mr. Janish was named Chief Transformation Officer in January 2019 and Executive Vice President of Global Operations and Supply Chain in October 2015. He served as Senior Vice President of International and Rx Operations from 2012 until 2015.

59

Roberto Khoury

Roberto Khoury was named Executive Vice President and President, Consumer Self Care International in May 2024. He joined Perrigo after more than six years with Kenvue (formerly a part of Johnson & Johnson), where he was Senior Vice President and General Manager of their skin care portfolio, including brand leadership responsibilities. Prior to that role he led Kenvue's consumer brands in Europe. Before his time at Kenvue, Mr. Khoury spent 13 years at L'Oréal, where he held several leadership roles in the consumer space that included stints in growing pan-European line extensions of leading brands.

44

Abbie Lennox

Abbie Lennox was named Executive Vice President and Chief Science Officer in January 2025. Ms. Lennox joins Perrigo from Bayer where she served as Executive Committee Member and Chief Trust and Science Officer from 2019 to 2024, responsible for leading the regulatory, medical affairs, safety and quality teams. Prior to her time at Bayer, she served in regulatory affairs leadership roles with Reckitt Benckiser, where she advanced the company’s regulatory approach to pipeline delivery across multiple health and wellness brands

44

Patrick Lockwood-Taylor

Patrick Lockwood-Taylor was appointed President, Chief Executive Officer and Board Member of Perrigo Company plc, effective June 30, 2023. He joined Perrigo from Bayer, where he was Regional President of Consumer Health North America, while also serving a dual role as President of Bayer U.S. Before Bayer, Mr. Lockwood-Taylor served as President and CEO of The Oneida Group Inc., a private company. Prior to this position, he spent more than 20 years with Procter & Gamble in various roles, including brand franchise and general management leadership positions.

56

Catherine T. Schmelter

Ms. Schmelter was named Executive Vice President and President Consumer Self-care Americas in September 2023. Prior to joining Perrigo, Ms. Schmelter was most recently at Treehouse Foods from 2016 to 2022, where she held various leadership positions, including Chief Transformation Officer. Prior to Treehouse Foods, Ms. Schmelter spent 10 years at Kraft Foods in various leadership roles, including Vice President of Meals, after beginning her CPG career at General Mills.

55

Robert Willis

Mr. Willis was named Executive Vice President and Chief Human Resources Officer in March 2019 after serving as Vice President of Human Resources Global Businesses for nearly six years. Prior to joining Perrigo, Mr. Willis gained more than 20 years of experience in Human Resources leadership through roles with Fawaz Alhokair Group, GE Capital, DoubleClick, and Norkom Technologies.

56

Our common equity has traded on the New York Stock Exchange under the symbol PRGO since June 6, 2013. Prior to that, our common equity traded on the Nasdaq Global Select Market under the same symbol.

As of February 21, 2025, there were 4,088 record holders of our ordinary shares.

In January 2003, the Board of Directors adopted a policy of paying quarterly dividends. During the year ended December 31, 2024, we declared and paid $152.5 million in dividends. We expect to continue the payment of cash dividends in the future, but there can be no assurance as to the amounts of any dividends declared or that the Board of Directors will continue to declare them.

The graph below shows a comparison of our cumulative total return with the cumulative total returns for the S&P 500 Index, and the S&P Consumer Staples Index. The graph assumes an investment of $100 at the beginning of the period and the reinvestment of any dividends. Information in the graph is presented for the years ended December 31, 2019 through December 31, 2024.

* $100 invested on December 31, 2019 - in stock or index - including reinvestment of dividends. Indexes calculated on month-end basis.

Our Board of Directors authorized up to $1.0 billion of share repurchases with no expiration date in October 2018, subject to the Board of Directors’ approval of the pricing parameters and amount that may be repurchased under each specific share repurchase program (the "2018 Authorization"). We did not repurchase any shares during the year ended December 31, 2024 or December 31, 2023. During the year ended December 31, 2021, we repurchased 3.4 million ordinary shares at an average purchase price of $48.28 per share for a total of $164.2 million under the 2018 Authorization. As of December 31, 2024, the approximate value of shares available for purchase under the 2018 Authorization was $835.8 million.

The following Management's Discussion and Analysis ("MD&A") is intended to provide readers with an understanding of our financial condition, results of operations, and cash flows by focusing on changes in certain key measures from year to year. This MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and accompanying Notes found in Item 8 of this report. See also "Cautionary Note Regarding Forward-Looking Statements." This discussion and analysis compares 2024 results to 2023. For discussion and analysis that compares 2023 results to 2022, see Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in Part II of our Annual Report on Form 10-K for the year ended December 31, 2023.

The Company’s plan to drive cash flow and total shareholder return is anchored behind its ‘Three-S’ plan – ‘Stabilizing’ Consumer Self-Care Americas store brand and infant formula businesses; ‘Streamlining’ the global portfolio, enterprise operating model and Consumer Self-Care International business; and ‘Strengthening’ what is working by prioritizing and increasing investments behind key ‘High-Grow’ brands.

Our fiscal year begins on January 1 and ends on December 31. We end our quarterly accounting periods on the Saturday closest to the end of the calendar quarter, with the fourth quarter ending on December 31 of each year.

        

•Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business in the U.S. and Canada.

•Consumer Self-Care International ("CSCI") comprises our consumer self-care business outside of the U.S. and Canada, primarily in Europe and Australia.

For information on each segment, our business environment, and competitive landscape, refer to Item 1. Business. For results by segment and geographic locations see below Segment Results and Item 8. Note 2 and Note 20.

Current macroeconomic conditions remain very dynamic, including impacts from inflation and interest rates, volatile changes in foreign currency exchange rates, political unrest and uncertainty and legislative and regulatory changes. Any causes of market size contraction could reduce our sales or erode our operating margin and consequently reduce our net earnings and cash flows.

Our interest expense is impacted by the overall global economic and interest rate environment. We manage interest rate risk through our capital structure and the use of interest rate swaps to fix the interest rate on greater than 90% of our outstanding debt.

Supply chain disruptions continue in specific categories such as agricultural commodities due to climate impacts, and with supply shortages due to the Middle East conflict. While reducing in impact, inflationary pressures are still a factor on cost in major economies globally across food, energy and labor. We continue to experience employment vacancies and attrition in the labor market which negatively impacts productivity and has driven the need for wage rate increases and other retention benefits. We implemented a series of actions to substantially mitigate these and other inflationary cost pressures, such as strategic pricing and our Supply Chain Reinvention Program. Benefits from our actions have substantially offset the impacts of inflation to date. However, future supply chain disruptions and inflationary pressures from the continuation of the conflicts between Russia and Ukraine and any escalating conflicts in the Middle East and neighboring regions are uncertain.

The invasion of Ukraine by Russia and resulting economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries on Russia, Belarus, and occupied regions in Ukraine have negatively impacted our results from operations in the region. Future impacts are difficult to predict due to the high level of uncertainty related to the war’s duration, evolution and resolution. If the conflict spreads or materially escalates, or economic conditions deteriorate, the impact on our business and results of operations could be material.

We continue to closely monitor the ongoing conflict and the social, political and economic environment in Israel and in the surrounding region to evaluate the impacts on our operations and supply chain. Israel is a global technology research and development center that plays a critical role to the global Active Pharmaceutical Ingredients ("API") market, as a number of key suppliers are located within Israel. The Company sources some raw materials and finished goods from suppliers in Israel for certain self-care products, including Omeprazole. To date, Perrigo has confirmed that our suppliers in the region have active operations and continue to manufacture materials for us, and we have not received any reports of restrictions on imports or exports in Israel. However, there is potential for some disruption as it relates to in-country logistics, including freight. As a precaution, Perrigo has engaged alternate suppliers to help minimize a potential supply disruption. If the conflict spreads or materially escalates, or if the conflict leads to further volatility and uncertainty in financial markets or economic conditions, the impact on our business and results of operations could be material. This includes the related events developing in the Red Sea and their potential to disrupt supply chains and lead to further inflationary pressures which we are also continuing to monitor closely.

We have both translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate impacts of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1) the impact from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances denominated in currencies other than the functional currency. Significant exchange rate fluctuations, especially in the Euro or the British Pound Sterling, have had, and could continue to have, a significant impact on our net sales, net earnings and cash flows.

As part of its efforts to prevent supply interruptions and risk of Cronobacter spp. illnesses associated with powdered infant formula, in March 2023, the FDA released an “Immediate National Strategy to Increase the Resiliency of the U.S. Infant Formula Market” and issued a letter to the powdered infant formula industry to share information to assist the industry in improving the microbiologic safety of powdered infant formula. In response to those changes, we made considerable investments in all our infant formula manufacturing sites. These investments included, among other things, enhancing our cleaning and sanitation protocols, our environmental monitoring programs, and quality oversight, as well as increasing the number of quality and operations personnel at the sites. These changes resulted in higher costs, lower manufacturing output, and lower production yields across our infant formula network.

As previously disclosed, the Company received a warning letter from the FDA on August 30, 2023 relating to the Perrigo Wisconsin infant formula facility, which was acquired from a third party in November 2022. While the Company was working to resolve the issues raised in the August 30 letter, on November 29, 2023, the Company received notice from the FDA of additional inspection observations relating to Perrigo Wisconsin. Consistent with the Company’s commitment to quality, the Company temporarily paused all production at that facility to address the FDA's observations. As part of this effort, the Company conducted an extended site-wide assessment and cleaning.

The Company also bolstered its internal resources and brought in additional outside expertise to help revise, enhance and strengthen comprehensive standards and processes across our infant formula network, including in some instances, pausing production for comprehensive cleaning and infrastructure improvements. All planned large-scale manufacturing plant improvements were completed in 2024, but the Company continues to implement the next phase of our quality enhancements, including further protocol, process and procedural improvements at the site level, and make additional investments to upgrade infrastructure. We do not expect these continuing improvements to result in extended shutdowns beyond those required for typical planned maintenance activities.

In October and November 2024, the FDA conducted its first inspection of the Perrigo Wisconsin infant formula facility since the November 2023 inspection. Following this 2024 inspection, the FDA did not issue written observations via a Form FDA 483.

Currently, all our infant formula manufacturing sites are up and running and have returned to reliable, quality-assured production with recent output across our infant formula network near historical levels. Our focus now lies in continuing to rebuild customer service levels and getting these critical products back on the shelves for consumers who need high-quality, affordable infant formula. With production now stabilized, we're driving strategic investments to strengthen the infant formula operations network to ensure the long-term sustainability of a key component of our CSCA business.

We have incurred certain extraordinary non-recurring costs associated with the remediation and enhancement actions described above and the evolving U.S. infant formula regulatory landscape, including consulting and legal fees relating to the Company’s responses to the FDA and the development and implementation of new protocols across our infant formula manufacturing sites, as well as other costs relating to the extended cleaning and sanitization and the pausing and restarting of production. Cash costs in 2024 to achieve the remediation and enhancement actions described above totaling $21.7 million were incurred. We also expect higher ongoing operating costs at our infant formula manufacturing sites moving forward as we continue to implement our enhanced program with additional internal capabilities. Due to these costs and the unabsorbed overhead and depressed sales volumes resulting from these actions, infant formula results in 2024 were below 2023 levels.

On July 29, 2024, the Antitrust Division of the U.S. Department of Justice advised us that it no longer considers Perrigo a subject or target of the division’s grand jury investigation of antitrust violations in the generic drug industry. That investigation had stemmed from the Company’s Rx Pharmaceuticals business, which was divested in 2021.

In 2022, we initiated a Supply Chain Reinvention Program to reduce structural costs, improve profitability and our service levels to our retail partners, and strengthen our resiliency by streamlining and simplifying our global supply chain. Through this initiative, we are reducing portfolio complexity, investing in advanced planning capabilities, diversifying sourcing, and optimizing our manufacturing assets and distribution models. We estimate a total annual run-rate potential savings opportunity by the end of fiscal year 2028 of between $200 million to $300 million (not including related depreciation expense on capital investments). To obtain these potential benefits, we anticipate incurring costs between $300 million to $350 million by the end of fiscal year 2028 to complete the program implementation, with the substantial portion of the costs incurred by the end of 2025, including capital investments, restructuring expenses and implementation costs. A significant portion of the annual run-rate potential savings of the Program, between $150 million to $200 million (not including related depreciation expense on capital investments), are anticipated by the end of fiscal year 2025. Refer to Item 8. Note 17 for further details on restructuring charges.

Perrigo has successfully transformed into a pure-play consumer self-care company and is now embarking on the next stage of its self-care journey - evolving to One Perrigo. This evolution will create sustainable, value accretive growth through a business model that better positions the Company to win in self-care.

As part of the Company's sustainable, value accretive growth strategy, the Company launched Project Energize - a global investment and efficiency program to drive the next evolution of capabilities and organizational agility. This three-year program is expected to produce significant benefits in the Company’s long-term business performance by enabling our One Perrigo growth strategy, increasing organizational agility and mitigating impacts from stabilizing and strengthening the infant formula business.

Project Energize was initiated in the first quarter of 2024, subject to local law and consultation requirements, and is expected to deliver annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026. The Company expects an annual reinvestment of approximately $40 million to $60 million of these savings to drive its business model. Restructuring and related charges associated with these actions are estimated to be in the range of $140 million to $160 million, including $20 million to $40 million in investments to enhance capabilities, and are expected to be substantially incurred by the end of 2026. Restructuring activities as part of Project Energize are expected to result in the net reduction of approximately 6% of total Perrigo roles. Refer to Item 8. Note 17 for further details on restructuring charges.

On September 17, 2024, Perrigo Finance Unlimited Company ("Perrigo Finance"), a public unlimited company incorporated under the laws of Ireland and an indirect wholly-owned finance subsidiary of Perrigo whose primary purpose is to finance the business and operations of Perrigo and its affiliates, issued $715 million in aggregate principal amount of 6.125% Senior Notes due 2032 (the "USD Notes due 2032") and €350 million in aggregate principal amount of 5.375% Senior Notes due 2032 (the "Euro Notes due 2032" and together with the USD Notes due 2032, the "2032 Notes"). Net proceeds from the 2032 Notes were used to prepay a portion of the Term Loan B Facility (as defined below) on September 19, 2024 and the remaining proceeds were used to fund the redemption of $700.0 million of the 4.375% Notes due 2026 on October 2, 2024.

In December 2024, we and the Borrower entered into Amendment No. 2, an Incremental Assumption Agreement to our Term Loan and Revolving Credit Agreement that provides for the refinancing of the Term B Loans outstanding under the Credit Agreement in the aggregate principal amount of $984.7 million. Refer to Item 8. Note 12.

On July 10, 2024, we completed the sale of our HRA Pharma Rare Diseases Business (the "Rare Diseases Business") to Esteve Healthcare S.L. ("ESTEVE") for total consideration of $244.5 million, inclusive of net cash received, an estimated working capital adjustment, and contingent consideration with a fair value of $34.5 million as of December 31, 2024. The sale resulted in a pre-tax gain of $5.8 million, net of professional fees, recorded in Other (income) expense, net on the Condensed Consolidated Statement of Operations within our CSCI segment. Refer to Item 8. Note 3 and Note 9 for additional details of the divestiture and impairments recognized as a result of the sale.

On November 1, 2024, we completed the sale of Orion Laboratories Hospital & Specialty Business (the "Hospital & Specialty Business") to General Pharma BidCo Pty Ltd, being an Australian incorporated entity which is ultimately owned by funds managed by Genesis Capital ("Genesis Capital") for total consideration of $13.3 million, which resulted in a pre-tax gain of $0.6 million, net of professional fees, recorded in Other (income) expense, net on the Consolidated Statements of Operations within our CSCI segment. Refer to Item 8. Note 3 and Note 9 for additional details of the divestiture and impairments recognized as a result of the sale.

Additionally, during the year ended December 31, 2024, we sold 7 branded products in 4 separate transactions for total cash consideration of $37.9 million, which resulted in a pre-tax gain of $28.1 million recorded in Other operating (income) expense, net on the Consolidated Statements of Operations within our CSCI segment.

Any currency translation effects described below represent estimates of the net differences between translation of foreign currency transactions into U.S. dollars for the year ended December 31, 2024 at the average exchange rates for the reporting period and average exchange rates for the year ended December 31, 2023.

•$206.1 million decrease, or 4.5%, due primarily to $179.2 million of lower net sales volumes, previously disclosed lost distribution of lower margin products, and a later start to the cough and cold season, primarily impacting the Pain & Sleep Aids, Upper Respiratory Digestive Health, and Oral Care categories compared to the prior year and $108.4 million of lower net sales in U.S. Nutrition category driven by actions to augment and strengthen infant formula network. These factors were partially offset by growth in Women's Health and Skin Care; and

•$50.6 million decrease from the divestitures of the Rare Diseases Business, Hospital and Specialty Business and the sale of branded products; and

•$15.1 million decrease from exited product lines; and

•$10.4 million decrease from unfavorable foreign currency translation.

•$137.7 million decrease in gross profit driven by the impact of lower global OTC net sales volumes resulting from a focus on production of higher margin products, including positive impacts from $57.1 million of new products, and lower infant formula volumes within U.S. Nutrition driven by actions to augment and strengthen the infant formula network. These lower sales volumes led to lower manufacturing productivity of $131.1 million which was partially offset by benefits from strategic pricing actions and savings achieved through Supply Chain Reinvention and Project Energize of $56.6 million. Additionally, exited products and divested businesses negatively impacted gross profit by $35.8 million and $17.5 million negative impact from infant formula remediation. Gross profit as a percentage of net sales decreased 80 basis points compared to the prior year due to the same factors that impacted gross profit; and

•$98.7 million decrease in operating expenses due primarily to lower selling and administrative costs of $149.4 million due primarily to Project Energize and lower variable employee costs. These decreases were partially offset by increased restructuring expense of approximately $68 million and higher advertising and promotion costs compared to the prior year.

•$253.0 million decrease, or 8.6%, due primarily to $178.3 million of lower net sales volumes, previously disclosed lost distribution of lower margin products, and a later start to the cough and cold season, primarily impacting the Pain & Sleep Aids, Upper Respiratory Digestive Health, and Oral Care categories compared to the prior year and $108.4 million of lower net sales in U.S. Nutrition category driven by actions to augment and strengthen infant formula network. These factors were partially offset by growth in Women's Health category, primarily driven by new product sales of Opill®; and

•$15.1 million decrease from exited product lines.

CSCA net sales by product category were as follows: